Title

0.1 All

Table 1:

Variable	Details	Total
N=		95
Sex	Feminin	21 (22.1%)
	Masculin	74 (77.9%)
Varsta	μ ±SD	65.54 ±8.33
	M (range)	66 (44:82)
IMC	μ ±SD	28.40 ±5.04
	M (range)	28.35 (19.49:38.68)
APP: fara	Da	35 (36.8%)
APP: DZ	Da	27 (28.4%)
APP: HTAE	Da	27 (28.4%)
APP: dislipidemie	Da	0
APP: obezitate	Da	9 (9.5%)
APP: sdr. metabolic	Da	0
APP: boala CV	Da	9 (9.5%)
APP oncologice	Da	6 (6.3%)
Dg FFH	HCC cunoscut	27 (28.7%)
	HCC de novo	59 (62.8%)
	HCC suspiciune	2 (2.1%)
	Formatiune hepatica benigna	3 (3.2%)
	Nodul displazic	3 (3.2%)
Ciroza hepatica	Da	83 (90.2%)
Etiologia CH	Etanolica	34 (36.6%)
	VHB	15 (16.1%)
	VHB+VHD	1 (1.1%)
	VHC	33 (35.5%)
	Hepatita autoimuna	0
	NASH	4 (4.3%)
	Boala wilson	0
	Boli colestatice	0
	Alte etiologii	6 (6.5%)
	Etilogie mixta	0
	Neprecizata	0
Consum alcool	Da	35 (42.2%)
Tratament FFH	Da	17 (18.3%)
Tratament antiviral	Da	23 (24.7%)
Data tratament antiviral	2013	1 (33.3%)
	2014-2019	1 (33.3%)
	2017	1 (33.3%)
Tip tratament antiviral	1	3 (13.6%)
	2	3 (13.6%)
	3	8 (36.4%)
	4	6 (27.3%)
	5	1 (4.5%)
	6	1 (4.5%)
RVS	Da	4 (26.7%)
Ascita	Da	27 (30.0%)
Grad ascita	1	8 (33.3%)
	2	6 (25.0%)
	3	10 (41.7%)
Encefalopatie hepatica	1	84 (93.3%)
	2	6 (6.7%)
Grad EH	1	3 (50.0%)
	2	2 (33.3%)
	3	1 (16.7%)
Child 1-child	1	45 (54.9%)
	2	31 (37.8%)
	3	6 (7.3%)
Puncte Clasa Child	μ ±SD	6.58 ±1.83
	M (range)	6 (2:12)
MELD	μ ±SD	11.50 ±4.03
	M (range)	11 (5:27)
MELD Na	μ ±SD	13.15 ±4.29
	M (range)	13 (6:27)
BCLC	A	35 (40.7%)
	B	21 (24.4%)
	C	25 (29.1%)
	D	5 (5.8%)
EDS	Da	69 (75.0%)
VE	Da	52 (72.2%)
Grad VE	1	21 (42.9%)
	2	24 (49.0%)
	3	4 (8.2%)
VG	1	68 (97.1%)
	2	2 (2.9%)
HDS	Da	10 (12.7%)
Aspect ficat US	Cirotic	80 (88.9%)
	Noncirotic	10 (11.1%)
Nr FFH US	1	47 (59.5%)
	2	15 (19.0%)
	3	3 (3.8%)
	4	14 (17.7%)
Localizare FFH US	μ ±SD	6.32 ±2.15
	M (range)	6 (2:11)
Contur FFH US	Bine delimitat	29 (72.5%)
	Cu contur difuz	11 (27.5%)
Aspect FFH US	Omogen	14 (25.0%)
	Inomogen	39 (69.6%)
	Aspect particular--nodul in nodul	3 (5.4%)
Calcifieri FFH US	Da	3 (4.2%)
Necroza FFH US	Da	9 (12.0%)
Doppler FFH US	Da	29 (42.6%)
Aspect Doppler FFH US	1	4 (14.3%)
	2	24 (85.7%)
Dimensiunea1 FFH US	μ ±SD	35.55 ±23.2
	M (range)	30 (1.54:121)
Dimensiunea2 FFH US	μ ±SD	37.87 ±28.5
	M (range)	29 (1.96:171)
Dimensiunea3 FFH US	μ ±SD	35.22 ±20.1
	M (range)	28.2 (15:70)
Tromboza VP US	Da	28 (41.2%)
Tip Tromboza VP US	Incompleta	9 (52.9%)
	Completa	8 (47.1%)
Etiologie tromboza VP US	Hematica	6 (33.3%)
	Maligna	12 (66.7%)
VP US	μ ±SD	15.98 ±13.4
	M (range)	13.3 (7:96)
Viteza VP US	μ ±SD	20.92 ±11.0
	M (range)	18.22 (7:60)
VS US	μ ±SD	9.03 ±2.71
	M (range)	8.8 (4:15)
Splina US	μ ±SD	136.34 ±33.8
	M (range)	136 (14:210)
HARI	μ ±SD	0.746 ±0.0781
	M (range)	0.75 (0.59:0.89)
SARI	μ ±SD	0.673 ±0.0976
	M (range)	0.68 (0.48:0.89)
LSM	Da	31 (34.8%)
Valoare LSM	μ ±SD	36.84 ±46.4
	M (range)	28.9 (5.3:270)
IQR LSM	μ ±SD	3.51 ±3.27
	M (range)	1.9 (0.3:13.2)
Elastografie SSM	Da	7 (22.6%)
Valoare SSM	μ ±SD	47.59 ±15.0
	M (range)	46.6 (21.2:75.5)
Fibroscan	Da	52 (55.9%)
Valoare Fibroscan	μ ±SD	33.93 ±23.8
	M (range)	29.8 (3.3:75)
CAP	Da	48 (96.0%)
Valoare CAP	μ ±SD	254.65 ±72.8
	M (range)	252.5 (100:395)
HVPG	1	50 (55.6%)
	2	40 (44.4%)
WHVP	μ ±SD	23.46 ±12.3
	M (range)	24 (4:82)
FHVP	μ ±SD	8.38 ±3.62
	M (range)	8 (2:22)
Valoare HVPG	μ ±SD	14.51 ±6.54
	M (range)	14 (3:29)
Biopsie FFH	Da	27 (35.5%)
Biopsie FFH2	Da	26 (34.2%)
Tip biopsie FFH	percutanata	9 (34.6%)
	intraoperatrie	3 (11.5%)
	piesa de rezectie	14 (53.8%)
Diagnostic histopat FFH	HCC	24 (92.3%)
	colangiocarcinom	1 (3.8%)
	alta leziune maligna	0
	leziune benigna	1 (3.8%)
	nodul displazic	0
Histopat HCC grad diferentiere	G1	3 (14.3%)
	G2	13 (61.9%)
	G3	5 (23.8%)
Histopat HCC Grad Edmontson Steiner	gr1	2 (14.3%)
	gr2	6 (42.9%)
	gr3	6 (42.9%)
	gr4	0
	na	0
Histopat microinvazie vasculara	Da	5 (45.5%)
Histopat margini rezectie	R0	3 (60.0%)
	R1	2 (40.0%)
Metastaze intraoperator	Da	2 (66.7%)
CT	Da	67 (72.8%)
Substanta contrast CT	Da	58 (98.3%)
LiRADS CT	?	1 (1.7%)
	3	2 (3.4%)
	4	1 (1.7%)
	5	55 (93.2%)
Nr FFH CT	1	31 (57.4%)
	2	6 (11.1%)
	3	17 (31.5%)
Metastaze CT	Da	1 (50.0%)
Ciroza CT	Da	55 (93.2%)
RMN	Da	30 (34.1%)
LiRADS RMN	3	2 (8.0%)
	4	4 (16.0%)
	5	19 (76.0%)
Nr FFH RMN	?	1 (4.3%)
	1	9 (39.1%)
	2	10 (43.5%)
	3	3 (13.0%)
Ciroza RMN	Da	21 (91.3%)
Tipul interventiei 1	1	2 (6.2%)
	2	13 (40.6%)
	3	8 (25.0%)
	4	0
	5	9 (28.1%)
Tip interventie nr 2	3	1 (33.3%)
	4	1 (33.3%)
	5	1 (33.3%)
Deces	Da	44 (46.8%)
AFP	μ ±SD	130.75 ±164.0
	M (range)	32.5 (2.2:412.8)
Hg	μ ±SD	13.35 ±2.27
	M (range)	13.7 (7.6:18)
PTL	μ ±SD	131.70 ±78.0
	M (range)	104 (26:428)
GOT	μ ±SD	58.95 ±35.6
	M (range)	47.5 (4:153)
GPT	μ ±SD	44.26 ±31.6
	M (range)	35.5 (7:182)
BT	μ ±SD	3.02 ±9.21
	M (range)	1.4 (0.3:85)
BD	μ ±SD	4.58 ±30.1
	M (range)	0.74 (0.07:285)
GGT	μ ±SD	137.01 ±124.0
	M (range)	96 (12:616)
FA	μ ±SD	355.79 ±219.7
	M (range)	305 (4.8:1244)
ALB	μ ±SD	4.93 ±5.96
	M (range)	3.7 (2.5:36)
INR	μ ±SD	1.28 ±0.283
	M (range)	1.26 (0.39:3.03)
COL	μ ±SD	157.96 ±55.3
	M (range)	147 (1.93:369)
TG	μ ±SD	100.10 ±47.8
	M (range)	89.5 (45:297)
Fe	μ ±SD	98.00 ±54.5
	M (range)	85.5 (14:257)
Crea	μ ±SD	0.90 ±0.334
	M (range)	0.85 (0.05:2.35)
Uree	μ ±SD	42.59 ±26.1
	M (range)	36 (0.92:189)
Na	μ ±SD	138.43 ±3.94
	M (range)	139 (123:146)
Glicemie	μ ±SD	121.23 ±38.7
	M (range)	112 (60:291)
Sange stocat	Da	4 (23.5%)
CEUS	Da	78 (86.7%)
Tip APHE CEUS	Izocaptanta	6 (7.9%)
	Hipercaptanta	70 (92.1%)
Caracterizare APHE CEUS	Inomogen	8 (61.5%)
	Omogen	5 (38.5%)
Viteza APHE CEUS	Lent impreuna cu parenchimul	2 (16.7%)
	Rapid, intens	10 (83.3%)
Wash out FFH CEUS	Da	67 (90.5%)
Tip wash out FFH CEUS	Precoce	5 (7.5%)
	Tardiv	62 (92.5%)
LiRADS CEUS	2	1 (1.5%)
	3	3 (4.5%)
	4	11 (16.7%)
	5	51 (77.3%)
μ ±SD = Mean (standard deviation); M (range) = Median (min:max);

0.2 CEUS 1

Table 2:

Variable	Details	Da	Nu	Total	Statistics
CEUS		78 (86.7%)	12 (13.3%)	90
Sex	Feminin	19 (24.4%)	1 (8.3%)	20 (22.2%)	OR=3.54 [0.43, 29.26] (p=0.287)
	Masculin	59 (75.6%)	11 (91.7%)	70 (77.8%)
Varsta	μ ±SD	66.19 ±7.76	59.08 ±10.1	65.54 ±8.33
	M (range)	66 (45:82)	59 (44:78)	66 (44:82)
IMC	μ ±SD	29.20 ±5.55	26.82 ±4.02	28.40 ±5.04
	M (range)	28.6 (19.49:38.68)	28.35 (20.86:29.7)	28.35 (19.49:38.68)
APP: fara	Da	31 (39.7%)	2 (16.7%)	33 (36.7%)	OR=3.30 [0.68, 16.08] (p=0.198)
APP: DZ	Da	19 (24.4%)	6 (50.0%)	25 (27.8%)	OR=0.32 [0.09, 1.12] (p=0.086)
APP: HTAE	Da	23 (29.5%)	4 (33.3%)	27 (30.0%)	OR=0.84 [0.23, 3.05] (p=0.747)
APP: dislipidemie	Da	0	0	0	OR=0.16 [0.00, 8.40] (p>0.999)
APP: obezitate	Da	8 (10.3%)	1 (8.3%)	9 (10.0%)	OR=1.26 [0.14, 11.05] (p>0.999)
APP: sdr. metabolic	Da	0	0	0	OR=0.16 [0.00, 8.40] (p>0.999)
APP: boala CV	Da	6 (7.7%)	2 (16.7%)	8 (8.9%)	OR=0.42 [0.07, 2.35] (p=0.289)
APP oncologice	Da	3 (3.8%)	1 (8.3%)	4 (4.4%)	OR=0.44 [0.04, 4.61] (p=0.442)
Dg FFH	HCC cunoscut	17 (22.1%)	7 (58.3%)	24 (27.0%)	V=0.31 (p=0.066)
	HCC de novo	55 (71.4%)	4 (33.3%)	59 (66.3%)
	HCC suspiciune	1 (1.3%)	0	1 (1.1%)
	Formatiune hepatica benigna	2 (2.6%)	0	2 (2.2%)
	Nodul displazic	2 (2.6%)	1 (8.3%)	3 (3.4%)
Ciroza hepatica	Da	71 (92.2%)	9 (75.0%)	80 (89.9%)	OR=3.94 [0.84, 18.58] (p=0.099)
Etiologia CH	Etanolica	29 (37.2%)	4 (33.3%)	33 (36.7%)	V=0.22 (p=0.524)
	VHB	13 (16.7%)	2 (16.7%)	15 (16.7%)
	VHB+VHD	1 (1.3%)	0	1 (1.1%)
	VHC	29 (37.2%)	3 (25.0%)	32 (35.6%)
	Hepatita autoimuna	0	0	0
	NASH	3 (3.8%)	1 (8.3%)	4 (4.4%)
	Boala wilson	0	0	0
	Boli colestatice	0	0	0
	Alte etiologii	3 (3.8%)	2 (16.7%)	5 (5.6%)
	Etilogie mixta	0	0	0
	Neprecizata	0	0	0
Consum alcool	Da	29 (41.4%)	5 (50.0%)	34 (42.5%)	OR=0.71 [0.19, 2.67] (p=0.736)
Tratament FFH	Da	14 (17.9%)	2 (16.7%)	16 (17.8%)	OR=1.09 [0.22, 5.55] (p>0.999)
Tratament antiviral	Da	22 (28.2%)	1 (8.3%)	23 (25.6%)	OR=4.32 [0.53, 35.49] (p=0.284)
Data tratament antiviral	2013	1 (33.3%)	0 (NA)	1 (33.3%)	V=NA (p>0.999)
	2014-2019	1 (33.3%)	0 (NA)	1 (33.3%)
	2017	1 (33.3%)	0 (NA)	1 (33.3%)
Tip tratament antiviral	1	3 (15.0%)	0	3 (14.3%)	V=>0.99 (p<0.001)
	2	3 (15.0%)	0	3 (14.3%)
	3	7 (35.0%)	0	7 (33.3%)
	4	6 (30.0%)	0	6 (28.6%)
	5	1 (5.0%)	0	1 (4.8%)
	6	0	1 (100%)	1 (4.8%)
RVS	Da	4 (28.6%)	0	4 (26.7%)	OR=1.29 [0.04, 37.98] (p>0.999)
Ascita	Da	24 (32.0%)	3 (25.0%)	27 (31.0%)	OR=1.41 [0.35, 5.69] (p=0.747)
Grad ascita	1	8 (36.4%)	0	8 (33.3%)	V=0.36 (p=0.217)
	2	6 (27.3%)	0	6 (25.0%)
	3	8 (36.4%)	2 (100%)	10 (41.7%)
Encefalopatie hepatica	1	70 (93.3%)	11 (91.7%)	81 (93.1%)	OR=1.27 [0.14, 11.95] (p>0.999)
	2	5 (6.7%)	1 (8.3%)	6 (6.9%)
Grad EH	1	3 (60.0%)	0	3 (50.0%)	V=>0.99 (p=0.050)
	2	2 (40.0%)	0	2 (33.3%)
	3	0	1 (100%)	1 (16.7%)
Child 1-child	1	39 (54.9%)	3 (37.5%)	42 (53.2%)	V=0.11 (p=0.620)
	2	27 (38.0%)	4 (50.0%)	31 (39.2%)
	3	5 (7.0%)	1 (12.5%)	6 (7.6%)
Puncte Clasa Child	μ ±SD	6.60 ±1.69	6.75 ±2.92	6.58 ±1.83
	M (range)	6 (3:11)	6.5 (2:12)	6 (2:12)
MELD	μ ±SD	11.52 ±4.06	12.88 ±3.6	11.50 ±4.03
	M (range)	11 (5:27)	12.5 (9:20)	11 (5:27)
MELD Na	μ ±SD	13.08 ±4.39	14.12 ±2.8	13.15 ±4.29
	M (range)	12 (7:27)	14 (11:20)	13 (6:27)
BCLC	A	34 (47.2%)	1 (8.3%)	35 (41.7%)	V=0.31 (p=0.049)
	B	17 (23.6%)	4 (33.3%)	21 (25.0%)
	C	18 (25.0%)	5 (41.7%)	23 (27.4%)
	D	3 (4.2%)	2 (16.7%)	5 (6.0%)
EDS	Da	61 (79.2%)	6 (50.0%)	67 (75.3%)	OR=3.81 [1.08, 13.42] (p=0.065)
VE	Da	45 (71.4%)	6 (85.7%)	51 (72.9%)	OR=0.42 [0.05, 3.71] (p=0.665)
Grad VE	1	17 (40.5%)	3 (50.0%)	20 (41.7%)	V=0.15 (p=0.587)
	2	22 (52.4%)	2 (33.3%)	24 (50.0%)
	3	3 (7.1%)	1 (16.7%)	4 (8.3%)
VG	1	59 (96.7%)	7 (100%)	66 (97.1%)	OR=1.59 [0.07, 36.29] (p>0.999)
	2	2 (3.3%)	0	2 (2.9%)
HDS	Da	8 (11.8%)	1 (11.1%)	9 (11.7%)	OR=1.07 [0.12, 9.68] (p>0.999)
Aspect ficat US	Cirotic	69 (92.0%)	8 (66.7%)	77 (88.5%)	OR=5.75 [1.33, 24.80] (p=0.029)
	Noncirotic	6 (8.0%)	4 (33.3%)	10 (11.5%)
Nr FFH US	1	42 (60.9%)	5 (55.6%)	47 (60.3%)	V=0.28 (p=0.101)
	2	14 (20.3%)	0	14 (17.9%)
	3	3 (4.3%)	0	3 (3.8%)
	4	10 (14.5%)	4 (44.4%)	14 (17.9%)
Localizare FFH US	μ ±SD	6.20 ±1.99	7.39 ±2.92	6.32 ±2.15
	M (range)	6 (2:11)	8 (2.3:11)	6 (2:11)
Contur FFH US	Bine delimitat	25 (73.5%)	3 (60.0%)	28 (71.8%)	OR=1.85 [0.26, 12.95] (p=0.609)
	Cu contur difuz	9 (26.5%)	2 (40.0%)	11 (28.2%)
Aspect FFH US	Omogen	12 (24.0%)	1 (20.0%)	13 (23.6%)	V=0.08 (p=0.821)
	Inomogen	35 (70.0%)	4 (80.0%)	39 (70.9%)
	Aspect particular--nodul in nodul	3 (6.0%)	0	3 (5.5%)
Calcifieri FFH US	Da	2 (3.3%)	1 (10.0%)	3 (4.2%)	OR=0.31 [0.03, 3.72] (p=0.370)
Necroza FFH US	Da	9 (14.1%)	0	9 (12.2%)	OR=3.59 [0.19, 66.60] (p=0.347)
Doppler FFH US	Da	26 (44.1%)	3 (33.3%)	29 (42.6%)	OR=1.58 [0.36, 6.91] (p=0.723)
Aspect Doppler FFH US	1	4 (16.0%)	0	4 (14.3%)	OR=1.47 [0.06, 33.60] (p>0.999)
	2	21 (84.0%)	3 (100%)	24 (85.7%)
Dimensiunea1 FFH US	μ ±SD	34.67 ±20.7	43.21 ±40.0	35.55 ±23.2
	M (range)	30 (1.54:90)	34.65 (2.86:121)	30 (1.54:121)
Dimensiunea2 FFH US	μ ±SD	36.01 ±20.7	50.53 ±61.7	37.87 ±28.5
	M (range)	29 (4.35:90)	31.15 (1.96:171)	29 (1.96:171)
Dimensiunea3 FFH US	μ ±SD	35.22 ±20.1		35.22 ±20.1
	M (range)	28.2 (15:70)		28.2 (15:70)
Tromboza VP US	Da	24 (40.7%)	4 (50.0%)	28 (41.8%)	OR=0.69 [0.16, 3.01] (p=0.711)
Tip Tromboza VP US	Incompleta	9 (56.2%)	0	9 (52.9%)	OR=3.80 [0.13, 107.31] (p=0.471)
	Completa	7 (43.8%)	1 (100%)	8 (47.1%)
Etiologie tromboza VP US	Hematica	6 (40.0%)	0	6 (33.3%)	OR=4.79 [0.21, 109.19] (p=0.515)
	Maligna	9 (60.0%)	3 (100%)	12 (66.7%)
VP US	μ ±SD	16.43 ±14.0	13.43 ±3.98	15.98 ±13.4
	M (range)	13.7 (8:96)	12.5 (10:17.8)	13.3 (7:96)
Viteza VP US	μ ±SD	21.20 ±11.2	15.00 ±NA	20.92 ±11.0
	M (range)	18.43 (7:60)	15 (15:15)	18.22 (7:60)
VS US	μ ±SD	9.00 ±2.63	9.30 ±4.81	9.03 ±2.71
	M (range)	8.8 (4:15)	9.3 (5.9:12.7)	8.8 (4:15)
Splina US	μ ±SD	139.22 ±35.7	122.85 ±17.6	136.34 ±33.8
	M (range)	137 (14:210)	124.05 (103.2:145)	136 (14:210)
HARI	μ ±SD	0.746 ±0.0781	0.747 ±0.095	0.746 ±0.0781
	M (range)	0.76 (0.59:0.89)	0.75 (0.65:0.84)	0.75 (0.59:0.89)
SARI	μ ±SD	0.675 ±0.0992	0.65 ±0.099	0.673 ±0.0976
	M (range)	0.68 (0.48:0.89)	0.65 (0.58:0.72)	0.68 (0.48:0.89)
LSM	Da	27 (36.0%)	4 (33.3%)	31 (35.6%)	OR=1.12 [0.31, 4.08] (p>0.999)
Valoare LSM	μ ±SD	40.21 ±49.5	20.57 ±17.8	36.84 ±46.4
	M (range)	33.5 (5.3:270)	16.95 (5.3:43.1)	28.9 (5.3:270)
IQR LSM	μ ±SD	3.65 ±3.41	2.61 ±2.51	3.51 ±3.27
	M (range)	2.15 (0.3:13.2)	1.9 (0.54:5.4)	1.9 (0.3:13.2)
Elastografie SSM	Da	6 (26.1%)	1 (14.3%)	7 (23.3%)	OR=2.12 [0.21, 21.39] (p>0.999)
Valoare SSM	μ ±SD	44.03 ±12.9	67.73 ±9.05	47.59 ±15.0
	M (range)	44.3 (21.2:69.44)	69.9 (57.8:75.5)	46.6 (21.2:75.5)
Fibroscan	Da	41 (52.6%)	9 (75.0%)	50 (55.6%)	OR=0.37 [0.09, 1.47] (p=0.214)
Valoare Fibroscan	μ ±SD	34.85 ±24.2	34.89 ±23.6	33.93 ±23.8
	M (range)	30 (3.3:75)	32.8 (4.8:75)	29.8 (3.3:75)
CAP	Da	38 (95.0%)	8 (100%)	46 (95.8%)	OR=0.91 [0.04, 20.64] (p>0.999)
Valoare CAP	μ ±SD	255.74 ±72.3	237.00 ±78.0	254.65 ±72.8
	M (range)	254.5 (100:395)	225 (122:361)	252.5 (100:395)
HVPG	1	38 (50.7%)	10 (83.3%)	48 (55.2%)	OR=0.21 [0.04, 1.00] (p=0.058)
	2	37 (49.3%)	2 (16.7%)	39 (44.8%)
WHVP	μ ±SD	22.43 ±7.48	40.33 ±36.9	23.46 ±12.3
	M (range)	24 (4:44)	27 (12:82)	24 (4:82)
FHVP	μ ±SD	8.54 ±3.74	8.00 ±1.0	8.38 ±3.62
	M (range)	8 (2:22)	8 (7:9)	8 (2:22)
Valoare HVPG	μ ±SD	14.95 ±6.48	12.33 ±6.66	14.51 ±6.54
	M (range)	14 (3:29)	14 (5:18)	14 (3:29)
Biopsie FFH	Da	21 (32.8%)	5 (50.0%)	26 (35.1%)	OR=0.49 [0.13, 1.87] (p=0.307)
Biopsie FFH2	Da	20 (31.2%)	5 (50.0%)	25 (33.8%)	OR=0.45 [0.12, 1.75] (p=0.290)
Tip biopsie FFH	percutanata	7 (31.8%)	1 (33.3%)	8 (32.0%)	V=0.25 (p=0.448)
	intraoperatrie	2 (9.1%)	1 (33.3%)	3 (12.0%)
	piesa de rezectie	13 (59.1%)	1 (33.3%)	14 (56.0%)
Diagnostic histopat FFH	HCC	21 (95.5%)	2 (66.7%)	23 (92.0%)	V=0.56 (p=0.021)
	colangiocarcinom	1 (4.5%)	0	1 (4.0%)
	alta leziune maligna	0	0	0
	leziune benigna	0	1 (33.3%)	1 (4.0%)
	nodul displazic	0	0	0
Histopat HCC grad diferentiere	G1	3 (15.8%)	0	3 (15.0%)	V=0.46 (p=0.122)
	G2	13 (68.4%)	0	13 (65.0%)
	G3	3 (15.8%)	1 (100%)	4 (20.0%)
Histopat HCC Grad Edmontson Steiner	gr1	2 (16.7%)	0	2 (15.4%)	V=0.37 (p=0.420)
	gr2	6 (50.0%)	0	6 (46.2%)
	gr3	4 (33.3%)	1 (100%)	5 (38.5%)
	gr4	0	0	0
	na	0	0	0
Histopat microinvazie vasculara	Da	4 (40.0%)	1 (100%)	5 (45.5%)	OR=0.23 [0.01, 7.05] (p=0.455)
Histopat margini rezectie	R0	3 (60.0%)	0 (NA)	3 (60.0%)	OR=1.40 [0.02, 97.43] (p>0.999)
	R1	2 (40.0%)	0 (NA)	2 (40.0%)
Metastaze intraoperator	Da	2 (66.7%)	0 (NA)	2 (66.7%)	OR=1.67 [0.02, 137.35] (p>0.999)
CT	Da	56 (71.8%)	9 (75.0%)	65 (72.2%)	OR=0.85 [0.21, 3.43] (p>0.999)
Substanta contrast CT	Da	50 (100%)	7 (87.5%)	57 (98.3%)	OR=20.20 [0.75, 542.89] (p=0.138)
LiRADS CT	?	1 (2.1%)	0	1 (1.8%)	V=0.19 (p=0.541)
	3	1 (2.1%)	1 (11.1%)	2 (3.5%)
	4	1 (2.1%)	0	1 (1.8%)
	5	45 (93.8%)	8 (88.9%)	53 (93.0%)
Nr FFH CT	1	27 (61.4%)	3 (37.5%)	30 (57.7%)	V=0.19 (p=0.404)
	2	5 (11.4%)	1 (12.5%)	6 (11.5%)
	3	12 (27.3%)	4 (50.0%)	16 (30.8%)
Metastaze CT	Da	1 (50.0%)	0 (NA)	1 (50.0%)	OR=1.00 [0.01, 92.42] (p>0.999)
Ciroza CT	Da	45 (91.8%)	8 (100%)	53 (93.0%)	OR=0.59 [0.03, 12.09] (p>0.999)
RMN	Da	27 (36.5%)	3 (25.0%)	30 (34.9%)	OR=1.72 [0.43, 6.92] (p=0.529)
LiRADS RMN	3	2 (9.1%)	0	2 (8.0%)	V=0.21 (p=0.584)
	4	4 (18.2%)	0	4 (16.0%)
	5	16 (72.7%)	3 (100%)	19 (76.0%)
Nr FFH RMN	?	0	1 (33.3%)	1 (4.3%)	V=0.62 (p=0.031)
	1	9 (45.0%)	0	9 (39.1%)
	2	8 (40.0%)	2 (66.7%)	10 (43.5%)
	3	3 (15.0%)	0	3 (13.0%)
Ciroza RMN	Da	19 (95.0%)	2 (66.7%)	21 (91.3%)	OR=9.50 [0.41, 217.61] (p=0.249)
Tipul interventiei 1	1	2 (6.7%)	0	2 (6.2%)	V=0.24 (p=0.594)
	2	13 (43.3%)	0	13 (40.6%)
	3	7 (23.3%)	1 (50.0%)	8 (25.0%)
	4	0	0	0
	5	8 (26.7%)	1 (50.0%)	9 (28.1%)
Tip interventie nr 2	3	1 (33.3%)	0 (NA)	1 (33.3%)	V=NA (p>0.999)
	4	1 (33.3%)	0 (NA)	1 (33.3%)
	5	1 (33.3%)	0 (NA)	1 (33.3%)
Deces	Da	33 (42.9%)	8 (66.7%)	41 (46.1%)	OR=0.38 [0.10, 1.35] (p=0.212)
AFP	μ ±SD	130.26 ±164.1	157.83 ±178.1	130.75 ±164.0
	M (range)	32.5 (2.2:412.8)	71.85 (5.5:400)	32.5 (2.2:412.8)
Hg	μ ±SD	13.37 ±2.18	13.12 ±3.09	13.35 ±2.27
	M (range)	13.65 (8.2:17.9)	14 (7.6:18)	13.7 (7.6:18)
PTL	μ ±SD	121.60 ±68.9	171.92 ±108.1	131.70 ±78.0
	M (range)	99.5 (26:428)	159 (40:366)	104 (26:428)
GOT	μ ±SD	57.46 ±34.2	64.91 ±38.0	58.95 ±35.6
	M (range)	45.5 (4:150)	56 (14:153)	47.5 (4:153)
GPT	μ ±SD	45.58 ±33.7	39.27 ±14.0	44.26 ±31.6
	M (range)	36 (7:182)	35 (22:64)	35.5 (7:182)
BT	μ ±SD	2.19 ±3.56	8.88 ±24.0	3.02 ±9.21
	M (range)	1.4 (0.3:26)	1.65 (0.4:85)	1.4 (0.3:85)
BD	μ ±SD	4.57 ±32.4	5.62 ±15.3	4.58 ±30.1
	M (range)	0.74 (0.07:285)	0.82 (0.13:54)	0.74 (0.07:285)
GGT	μ ±SD	140.05 ±130.1	116.42 ±80.3	137.01 ±124.0
	M (range)	94 (12:616)	103 (31:294)	96 (12:616)
FA	μ ±SD	350.63 ±218.8	410.25 ±246.4	355.79 ±219.7
	M (range)	304.5 (4.8:1244)	343 (175:1119)	305 (4.8:1244)
ALB	μ ±SD	4.75 ±5.41	6.23 ±9.41	4.93 ±5.96
	M (range)	3.75 (2.5:36)	3.65 (2.5:36)	3.7 (2.5:36)
INR	μ ±SD	1.28 ±0.3	1.28 ±0.173	1.28 ±0.283
	M (range)	1.29 (0.39:3.03)	1.25 (1:1.52)	1.26 (0.39:3.03)
COL	μ ±SD	157.33 ±50.7	135.59 ±79.0	157.96 ±55.3
	M (range)	147 (83:369)	166 (1.93:197)	147 (1.93:369)
TG	μ ±SD	95.28 ±42.3	101.40 ±21.0	100.10 ±47.8
	M (range)	84.5 (45:272)	97 (85:137)	89.5 (45:297)
Fe	μ ±SD	95.63 ±51.8	135.14 ±72.0	98.00 ±54.5
	M (range)	84.5 (14:257)	149 (42:228)	85.5 (14:257)
Crea	μ ±SD	0.894 ±0.343	0.983 ±0.306	0.90 ±0.334
	M (range)	0.86 (0.05:2.35)	0.81 (0.71:1.59)	0.85 (0.05:2.35)
Uree	μ ±SD	42.66 ±26.4	45.33 ±27.7	42.59 ±26.1
	M (range)	37 (17:189)	36.5 (0.92:111)	36 (0.92:189)
Na	μ ±SD	138.42 ±3.95	138.67 ±3.06	138.43 ±3.94
	M (range)	139 (123:146)	139 (132:144)	139 (123:146)
Glicemie	μ ±SD	123.05 ±40.0	111.98 ±32.7	121.23 ±38.7
	M (range)	115 (60:291)	105 (67:191)	112 (60:291)
Sange stocat	Da	3 (23.1%)	0	3 (20.0%)	OR=1.67 [0.06, 43.79] (p>0.999)
Tip APHE CEUS	Izocaptanta	6 (7.9%)	0 (NA)	6 (7.9%)	OR=0.09 [0.00, 5.04] (p>0.999)
	Hipercaptanta	70 (92.1%)	0 (NA)	70 (92.1%)
Caracterizare APHE CEUS	Inomogen	8 (61.5%)	0 (NA)	8 (61.5%)	OR=1.55 [0.03, 89.96] (p>0.999)
	Omogen	5 (38.5%)	0 (NA)	5 (38.5%)
Viteza APHE CEUS	Lent impreuna cu parenchimul	2 (16.7%)	0 (NA)	2 (16.7%)	OR=0.24 [0.00, 15.19] (p>0.999)
	Rapid, intens	10 (83.3%)	0 (NA)	10 (83.3%)
Wash out FFH CEUS	Da	67 (90.5%)	0 (NA)	67 (90.5%)	OR=9.00 [0.17, 487.40] (p>0.999)
Tip wash out FFH CEUS	Precoce	5 (7.5%)	0 (NA)	5 (7.5%)	OR=0.09 [0.00, 4.88] (p>0.999)
	Tardiv	62 (92.5%)	0 (NA)	62 (92.5%)
LiRADS CEUS	2	1 (1.5%)	0 (NA)	1 (1.5%)	V=NA (p>0.999)
	3	3 (4.5%)	0 (NA)	3 (4.5%)
	4	11 (16.7%)	0 (NA)	11 (16.7%)
	5	51 (77.3%)	0 (NA)	51 (77.3%)
μ ±SD = Mean (standard deviation); M (range) = Median (min:max); Welch = Welch T-Test (not assuming equal variances); OR/RR = odds-ratio / risk-ratio [95% CI] and p value from Fisher test);

0.3 Tip_APHE_CEUS

Table 2:

Variable	Details	Izocaptanta	Hipercaptanta	Total	Statistics
Tip APHE CEUS		6 (7.9%)	70 (92.1%)	76
Sex	Feminin	1 (16.7%)	18 (25.7%)	19 (25.0%)	OR=0.58 [0.06, 5.28] (p>0.999)
	Masculin	5 (83.3%)	52 (74.3%)	57 (75.0%)
Varsta	μ ±SD	66.50 ±6.53	66.34 ±7.94	65.54 ±8.33
	M (range)	69 (55:73)	66 (45:82)	66 (44:82)
IMC	μ ±SD	27.73 ±NA	29.41 ±5.96	28.40 ±5.04
	M (range)	27.73 (27.73:27.73)	29.3 (19.49:38.68)	28.35 (19.49:38.68)
APP: fara	Da	2 (33.3%)	28 (40.0%)	30 (39.5%)	OR=0.75 [0.13, 4.37] (p>0.999)
APP: DZ	Da	1 (16.7%)	17 (24.3%)	18 (23.7%)	OR=0.62 [0.07, 5.71] (p>0.999)
APP: HTAE	Da	2 (33.3%)	21 (30.0%)	23 (30.3%)	OR=1.17 [0.20, 6.87] (p>0.999)
APP: dislipidemie	Da	0	0	0	OR=10.85 [0.20, 593.02] (p>0.999)
APP: obezitate	Da	0	8 (11.4%)	8 (10.5%)	OR=0.57 [0.03, 10.96] (p>0.999)
APP: sdr. metabolic	Da	0	0	0	OR=10.85 [0.20, 593.02] (p>0.999)
APP: boala CV	Da	1 (16.7%)	5 (7.1%)	6 (7.9%)	OR=2.60 [0.25, 26.77] (p=0.400)
APP oncologice	Da	0	3 (4.3%)	3 (3.9%)	OR=1.48 [0.07, 31.98] (p>0.999)
Dg FFH	HCC cunoscut	1 (16.7%)	14 (20.3%)	15 (20.0%)	V=0.37 (p=0.037)
	HCC de novo	3 (50.0%)	52 (75.4%)	55 (73.3%)
	HCC suspiciune	0	1 (1.4%)	1 (1.3%)
	Formatiune hepatica benigna	1 (16.7%)	1 (1.4%)	2 (2.7%)
	Nodul displazic	1 (16.7%)	1 (1.4%)	2 (2.7%)
Ciroza hepatica	Da	5 (83.3%)	64 (92.8%)	69 (92.0%)	OR=0.39 [0.04, 4.02] (p=0.405)
Etiologia CH	Etanolica	1 (16.7%)	26 (37.1%)	27 (35.5%)	V=0.25 (p=0.453)
	VHB	2 (33.3%)	11 (15.7%)	13 (17.1%)
	VHB+VHD	0	1 (1.4%)	1 (1.3%)
	VHC	2 (33.3%)	27 (38.6%)	29 (38.2%)
	Hepatita autoimuna	0	0	0
	NASH	1 (16.7%)	2 (2.9%)	3 (3.9%)
	Boala wilson	0	0	0
	Boli colestatice	0	0	0
	Alte etiologii	0	3 (4.3%)	3 (3.9%)
	Etilogie mixta	0	0	0
	Neprecizata	0	0	0
Consum alcool	Da	1 (20.0%)	27 (42.2%)	28 (40.6%)	OR=0.34 [0.04, 3.24] (p=0.641)
Tratament FFH	Da	2 (33.3%)	12 (17.1%)	14 (18.4%)	OR=2.42 [0.40, 14.73] (p=0.304)
Tratament antiviral	Da	2 (33.3%)	20 (28.6%)	22 (28.9%)	OR=1.25 [0.21, 7.37] (p>0.999)
Data tratament antiviral	2013	0 (NA)	1 (33.3%)	1 (33.3%)	V=NA (p>0.999)
	2014-2019	0 (NA)	1 (33.3%)	1 (33.3%)
	2017	0 (NA)	1 (33.3%)	1 (33.3%)
Tip tratament antiviral	1	0	3 (16.7%)	3 (15.0%)	V=0.25 (p=0.875)
	2	0	3 (16.7%)	3 (15.0%)
	3	1 (50.0%)	6 (33.3%)	7 (35.0%)
	4	1 (50.0%)	5 (27.8%)	6 (30.0%)
	5	0	1 (5.6%)	1 (5.0%)
	6	0	0	0
RVS	Da	0 (NA)	4 (28.6%)	4 (28.6%)	OR=2.33 [0.04, 136.98] (p>0.999)
Ascita	Da	1 (20.0%)	22 (32.4%)	23 (31.5%)	OR=0.52 [0.06, 4.96] (p>0.999)
Grad ascita	1	0	8 (40.0%)	8 (38.1%)	V=0.35 (p=0.269)
	2	1 (100%)	5 (25.0%)	6 (28.6%)
	3	0	7 (35.0%)	7 (33.3%)
Encefalopatie hepatica	1	6 (100%)	62 (92.5%)	68 (93.2%)	OR=1.14 [0.06, 23.11] (p>0.999)
	2	0	5 (7.5%)	5 (6.8%)
Grad EH	1	0 (NA)	3 (60.0%)	3 (60.0%)	V=NA (p>0.999)
	2	0 (NA)	2 (40.0%)	2 (40.0%)
	3	0 (NA)	0	0
Child 1-child	1	3 (50.0%)	35 (55.6%)	38 (55.1%)	V=0.11 (p=0.648)
	2	2 (33.3%)	24 (38.1%)	26 (37.7%)
	3	1 (16.7%)	4 (6.3%)	5 (7.2%)
Puncte Clasa Child	μ ±SD	6.80 ±2.17	6.61 ±1.67	6.58 ±1.83
	M (range)	6 (5:10)	6 (3:11)	6 (2:12)
MELD	μ ±SD	12.60 ±4.72	11.40 ±4.09	11.50 ±4.03
	M (range)	13 (6:19)	11 (5:27)	11 (5:27)
MELD Na	μ ±SD	12.80 ±4.38	13.07 ±4.46	13.15 ±4.29
	M (range)	13 (7:19)	12 (7:27)	13 (6:27)
BCLC	A	2 (50.0%)	32 (48.5%)	34 (48.6%)	V=0.05 (p=0.979)
	B	1 (25.0%)	15 (22.7%)	16 (22.9%)
	C	1 (25.0%)	16 (24.2%)	17 (24.3%)
	D	0	3 (4.5%)	3 (4.3%)
EDS	Da	6 (100%)	54 (78.3%)	60 (80.0%)	OR=3.70 [0.20, 69.33] (p=0.339)
VE	Da	3 (50.0%)	41 (73.2%)	44 (71.0%)	OR=0.37 [0.07, 2.01] (p=0.344)
Grad VE	1	1 (33.3%)	15 (39.5%)	16 (39.0%)	V=0.28 (p=0.195)
	2	1 (33.3%)	21 (55.3%)	22 (53.7%)
	3	1 (33.3%)	2 (5.3%)	3 (7.3%)
VG	1	6 (100%)	52 (96.3%)	58 (96.7%)	OR=0.62 [0.03, 14.36] (p>0.999)
	2	0	2 (3.7%)	2 (3.3%)
HDS	Da	0	8 (13.1%)	8 (11.9%)	OR=0.48 [0.02, 9.40] (p>0.999)
Aspect ficat US	Cirotic	6 (100%)	61 (91.0%)	67 (91.8%)	OR=1.37 [0.07, 27.26] (p>0.999)
	Noncirotic	0	6 (9.0%)	6 (8.2%)
Nr FFH US	1	4 (80.0%)	36 (58.1%)	40 (59.7%)	V=0.28 (p=0.157)
	2	0	14 (22.6%)	14 (20.9%)
	3	1 (20.0%)	2 (3.2%)	3 (4.5%)
	4	0	10 (16.1%)	10 (14.9%)
Localizare FFH US	μ ±SD	6.20 ±1.66	6.19 ±2.04	6.32 ±2.15
	M (range)	6 (4.5:8)	6 (2:11)	6 (2:11)
Contur FFH US	Bine delimitat	1 (33.3%)	22 (75.9%)	23 (71.9%)	OR=0.16 [0.01, 2.03] (p=0.184)
	Cu contur difuz	2 (66.7%)	7 (24.1%)	9 (28.1%)
Aspect FFH US	Omogen	2 (33.3%)	10 (23.8%)	12 (25.0%)	V=0.11 (p=0.732)
	Inomogen	4 (66.7%)	29 (69.0%)	33 (68.8%)
	Aspect particular--nodul in nodul	0	3 (7.1%)	3 (6.2%)
Calcifieri FFH US	Da	2 (33.3%)	0	2 (3.3%)	OR=60.56 [2.51, 1 463.33] (p=0.008)
Necroza FFH US	Da	2 (33.3%)	6 (10.7%)	8 (12.9%)	OR=4.17 [0.63, 27.77] (p=0.168)
Doppler FFH US	Da	4 (66.7%)	20 (39.2%)	24 (42.1%)	OR=3.10 [0.52, 18.53] (p=0.227)
Aspect Doppler FFH US	1	2 (50.0%)	2 (10.5%)	4 (17.4%)	OR=8.50 [0.74, 98.21] (p=0.125)
	2	2 (50.0%)	17 (89.5%)	19 (82.6%)
Dimensiunea1 FFH US	μ ±SD	20.60 ±9.29	36.02 ±20.9	35.55 ±23.2
	M (range)	19 (9:30)	32 (1.54:90)	30 (1.54:121)
Dimensiunea2 FFH US	μ ±SD	16.50 ±4.95	36.75 ±21.0	37.87 ±28.5
	M (range)	16.5 (13:20)	29.5 (4.35:90)	29 (1.96:171)
Dimensiunea3 FFH US	μ ±SD	17.95 ±1.34	37.13 ±20.3	35.22 ±20.1
	M (range)	17.95 (17:18.9)	29 (15:70)	28.2 (15:70)
Tromboza VP US	Da	0	23 (41.8%)	23 (39.7%)	OR=0.20 [0.01, 4.01] (p=0.270)
Tip Tromboza VP US	Incompleta	0 (NA)	8 (53.3%)	8 (53.3%)	OR=0.88 [0.02, 50.19] (p>0.999)
	Completa	0 (NA)	7 (46.7%)	7 (46.7%)
Etiologie tromboza VP US	Hematica	0 (NA)	5 (35.7%)	5 (35.7%)	OR=1.73 [0.03, 99.95] (p>0.999)
	Maligna	0 (NA)	9 (64.3%)	9 (64.3%)
VP US	μ ±SD	29.64 ±37.2	14.20 ±3.94	15.98 ±13.4
	M (range)	13.2 (10:96)	13.7 (8:28)	13.3 (7:96)
Viteza VP US	μ ±SD	19.72 ±5.26	20.88 ±11.8	20.92 ±11.0
	M (range)	19.72 (16:23.44)	18.22 (7:60)	18.22 (7:60)
VS US	μ ±SD	5.40 ±1.98	9.36 ±2.44	9.03 ±2.71
	M (range)	5.4 (4:6.8)	9 (6:15)	8.8 (4:15)
Splina US	μ ±SD	135.64 ±37.0	141.44 ±29.0	136.34 ±33.8
	M (range)	115.8 (110:196)	138.5 (86:210)	136 (14:210)
HARI	μ ±SD	0.767 ±0.0929	0.742 ±0.0794	0.746 ±0.0781
	M (range)	0.81 (0.66:0.83)	0.74 (0.59:0.89)	0.75 (0.59:0.89)
SARI	μ ±SD	0.56 ±NA	0.68 ±0.1	0.673 ±0.0976
	M (range)	0.56 (0.56:0.56)	0.7 (0.48:0.89)	0.68 (0.48:0.89)
LSM	Da	4 (66.7%)	22 (32.8%)	26 (35.6%)	OR=4.09 [0.70, 24.07] (p=0.178)
Valoare LSM	μ ±SD	44.20 ±26.8	40.16 ±54.1	36.84 ±46.4
	M (range)	47.6 (11.6:70)	33 (5.3:270)	28.9 (5.3:270)
IQR LSM	μ ±SD	10.50 ±3.82	3.03 ±2.44	3.51 ±3.27
	M (range)	10.5 (7.8:13.2)	1.8 (0.3:7.9)	1.9 (0.3:13.2)
Elastografie SSM	Da	0	6 (27.3%)	6 (26.1%)	OR=0.85 [0.03, 23.56] (p>0.999)
Valoare SSM	μ ±SD	28.30 ±NA	45.02 ±12.7	47.59 ±15.0
	M (range)	28.3 (28.3:28.3)	45.4 (21.2:69.44)	46.6 (21.2:75.5)
Fibroscan	Da	2 (33.3%)	39 (55.7%)	41 (53.9%)	OR=0.40 [0.07, 2.31] (p=0.405)
Valoare Fibroscan	μ ±SD	35.00 ±1.41	34.84 ±24.8	33.93 ±23.8
	M (range)	35 (34:36)	29.6 (3.3:75)	29.8 (3.3:75)
CAP	Da	2 (100%)	36 (94.7%)	38 (95.0%)	OR=0.34 [0.01, 9.24] (p>0.999)
Valoare CAP	μ ±SD	251.00 ±11.3	256.00 ±74.3	254.65 ±72.8
	M (range)	251 (243:259)	254.5 (100:395)	252.5 (100:395)
HVPG	1	5 (83.3%)	32 (47.8%)	37 (50.7%)	OR=5.47 [0.61, 49.35] (p=0.199)
	2	1 (16.7%)	35 (52.2%)	36 (49.3%)
WHVP	μ ±SD	19.00 ±NA	22.33 ±7.6	23.46 ±12.3
	M (range)	19 (19:19)	24 (4:44)	24 (4:82)
FHVP	μ ±SD	8.00 ±NA	8.67 ±3.81	8.38 ±3.62
	M (range)	8 (8:8)	8 (2:22)	8 (2:22)
Valoare HVPG	μ ±SD	11.00 ±NA	14.80 ±6.45	14.51 ±6.54
	M (range)	11 (11:11)	14 (3:29)	14 (3:29)
Biopsie FFH	Da	1 (25.0%)	20 (33.9%)	21 (33.3%)	OR=0.65 [0.06, 6.66] (p>0.999)
Biopsie FFH2	Da	0	20 (33.9%)	20 (31.7%)	OR=0.21 [0.01, 4.17] (p=0.298)
Tip biopsie FFH	percutanata	0 (NA)	7 (31.8%)	7 (31.8%)	V=NA (p>0.999)
	intraoperatrie	0 (NA)	2 (9.1%)	2 (9.1%)
	piesa de rezectie	0 (NA)	13 (59.1%)	13 (59.1%)
Diagnostic histopat FFH	HCC	0 (NA)	21 (95.5%)	21 (95.5%)	V=NA (p>0.999)
	colangiocarcinom	0 (NA)	1 (4.5%)	1 (4.5%)
	alta leziune maligna	0 (NA)	0	0
	leziune benigna	0 (NA)	0	0
	nodul displazic	0 (NA)	0	0
Histopat HCC grad diferentiere	G1	0 (NA)	3 (15.8%)	3 (15.8%)	V=NA (p>0.999)
	G2	0 (NA)	13 (68.4%)	13 (68.4%)
	G3	0 (NA)	3 (15.8%)	3 (15.8%)
Histopat HCC Grad Edmontson Steiner	gr1	0 (NA)	2 (16.7%)	2 (16.7%)	V=NA (p>0.999)
	gr2	0 (NA)	6 (50.0%)	6 (50.0%)
	gr3	0 (NA)	4 (33.3%)	4 (33.3%)
	gr4	0 (NA)	0	0
	na	0 (NA)	0	0
Histopat microinvazie vasculara	Da	0 (NA)	4 (40.0%)	4 (40.0%)	OR=1.44 [0.02, 87.16] (p>0.999)
Histopat margini rezectie	R0	0 (NA)	3 (60.0%)	3 (60.0%)	OR=0.71 [0.01, 49.71] (p>0.999)
	R1	0 (NA)	2 (40.0%)	2 (40.0%)
Metastaze intraoperator	Da	0 (NA)	2 (66.7%)	2 (66.7%)	OR=0.60 [0.01, 49.45] (p>0.999)
CT	Da	4 (66.7%)	50 (71.4%)	54 (71.1%)	OR=0.80 [0.14, 4.72] (p>0.999)
Substanta contrast CT	Da	3 (100%)	45 (100%)	48 (100%)	OR=0.08 [0.00, 4.49] (p>0.999)
LiRADS CT	?	0	1 (2.3%)	1 (2.1%)	V=0.08 (p=0.960)
	3	0	1 (2.3%)	1 (2.1%)
	4	0	1 (2.3%)	1 (2.1%)
	5	4 (100%)	40 (93.0%)	44 (93.6%)
Nr FFH CT	1	2 (50.0%)	23 (60.5%)	25 (59.5%)	V=0.13 (p=0.696)
	2	1 (25.0%)	4 (10.5%)	5 (11.9%)
	3	1 (25.0%)	11 (28.9%)	12 (28.6%)
Metastaze CT	Da	0 (NA)	1 (50.0%)	1 (50.0%)	OR=1.00 [0.01, 92.42] (p>0.999)
Ciroza CT	Da	4 (100%)	39 (90.7%)	43 (91.5%)	OR=1.03 [0.05, 22.31] (p>0.999)
RMN	Da	2 (33.3%)	24 (36.4%)	26 (36.1%)	OR=0.87 [0.15, 5.14] (p>0.999)
LiRADS RMN	3	1 (50.0%)	1 (5.3%)	2 (9.5%)	V=0.56 (p=0.039)
	4	1 (50.0%)	3 (15.8%)	4 (19.0%)
	5	0	15 (78.9%)	15 (71.4%)
Nr FFH RMN	?	0	0	0	V=0.37 (p=0.257)
	1	1 (50.0%)	8 (44.4%)	9 (45.0%)
	2	0	8 (44.4%)	8 (40.0%)
	3	1 (50.0%)	2 (11.1%)	3 (15.0%)
Ciroza RMN	Da	2 (100%)	17 (94.4%)	19 (95.0%)	OR=0.43 [0.01, 13.69] (p>0.999)
Tipul interventiei 1	1	0	2 (6.9%)	2 (6.7%)	V=0.34 (p=0.334)
	2	0	13 (44.8%)	13 (43.3%)
	3	1 (100%)	6 (20.7%)	7 (23.3%)
	4	0	0	0
	5	0	8 (27.6%)	8 (26.7%)
Tip interventie nr 2	3	0 (NA)	1 (33.3%)	1 (33.3%)	V=NA (p>0.999)
	4	0 (NA)	1 (33.3%)	1 (33.3%)
	5	0 (NA)	1 (33.3%)	1 (33.3%)
Deces	Da	1 (16.7%)	31 (44.9%)	32 (42.7%)	OR=0.25 [0.03, 2.21] (p=0.231)
AFP	μ ±SD	25.93 ±34.1	140.37 ±169.6	130.75 ±164.0
	M (range)	16.4 (2.2:94)	36.6 (2.2:412.8)	32.5 (2.2:412.8)
Hg	μ ±SD	14.53 ±0.873	13.30 ±2.25	13.35 ±2.27
	M (range)	14.4 (13.3:15.8)	13.55 (8.2:17.9)	13.7 (7.6:18)
PTL	μ ±SD	142.17 ±53.4	120.17 ±70.9	131.70 ±78.0
	M (range)	128 (76:226)	98.5 (26:428)	104 (26:428)
GOT	μ ±SD	48.33 ±21.5	58.87 ±35.3	58.95 ±35.6
	M (range)	41 (24:85)	47.5 (4:150)	47.5 (4:153)
GPT	μ ±SD	32.00 ±12.3	46.90 ±35.2	44.26 ±31.6
	M (range)	27.5 (23:55)	36.5 (7:182)	35.5 (7:182)
BT	μ ±SD	5.25 ±7.04	1.96 ±3.1	3.02 ±9.21
	M (range)	2.65 (0.7:19)	1.4 (0.3:26)	1.4 (0.3:85)
BD	μ ±SD	1.20 ±1.16	4.93 ±34.0	4.58 ±30.1
	M (range)	0.38 (0.31:2.6)	0.74 (0.07:285)	0.74 (0.07:285)
GGT	μ ±SD	139.17 ±220.6	140.52 ±123.5	137.01 ±124.0
	M (range)	51 (17:586)	94 (12:616)	96 (12:616)
FA	μ ±SD	312.00 ±113.8	353.10 ±227.9	355.79 ±219.7
	M (range)	306 (193:502)	304 (4.8:1244)	305 (4.8:1244)
ALB	μ ±SD	3.48 ±0.462	4.48 ±4.63	4.93 ±5.96
	M (range)	3.55 (2.8:4)	3.8 (2.5:36)	3.7 (2.5:36)
INR	μ ±SD	1.49 ±0.299	1.27 ±0.299	1.28 ±0.283
	M (range)	1.54 (1.07:1.8)	1.26 (0.39:3.03)	1.26 (0.39:3.03)
COL	μ ±SD	165.75 ±25.8	157.11 ±52.8	157.96 ±55.3
	M (range)	161.5 (139:201)	145 (83:369)	147 (1.93:369)
TG	μ ±SD	98.50 ±25.5	95.29 ±44.1	100.10 ±47.8
	M (range)	97.5 (76:123)	87 (45:272)	89.5 (45:297)
Fe	μ ±SD	128.17 ±53.7	92.58 ±51.2	98.00 ±54.5
	M (range)	115.5 (59:209)	82 (14:257)	85.5 (14:257)
Crea	μ ±SD	0.823 ±0.305	0.901 ±0.352	0.90 ±0.334
	M (range)	0.72 (0.6:1.42)	0.88 (0.05:2.35)	0.85 (0.05:2.35)
Uree	μ ±SD	33.50 ±11.6	43.39 ±27.5	42.59 ±26.1
	M (range)	30 (22:50)	37 (17:189)	36 (0.92:189)
Na	μ ±SD	140.33 ±5.85	138.32 ±3.78	138.43 ±3.94
	M (range)	141.5 (129:146)	139 (123:146)	139 (123:146)
Glicemie	μ ±SD	111.36 ±18.5	123.95 ±41.9	121.23 ±38.7
	M (range)	106 (90.8:140)	114 (60:291)	112 (60:291)
Sange stocat	Da	0	3 (27.3%)	3 (25.0%)	OR=0.81 [0.03, 25.10] (p>0.999)
CEUS	Da	6 (100%)	70 (100%)	76 (100%)	OR=0.09 [0.00, 5.04] (p>0.999)
Caracterizare APHE CEUS	Inomogen	0 (NA)	8 (61.5%)	8 (61.5%)	OR=0.65 [0.01, 37.66] (p>0.999)
	Omogen	0 (NA)	5 (38.5%)	5 (38.5%)
Viteza APHE CEUS	Lent impreuna cu parenchimul	1 (100%)	1 (9.1%)	2 (16.7%)	OR=21.00 [0.56, 791.29] (p=0.167)
	Rapid, intens	0	10 (90.9%)	10 (83.3%)
Wash out FFH CEUS	Da	5 (83.3%)	62 (91.2%)	67 (90.5%)	OR=0.48 [0.05, 4.85] (p=0.461)
Tip wash out FFH CEUS	Precoce	0	5 (8.1%)	5 (7.5%)	OR=0.95 [0.05, 19.56] (p>0.999)
	Tardiv	5 (100%)	57 (91.9%)	62 (92.5%)
LiRADS CEUS	2	0	1 (1.6%)	1 (1.5%)	V=0.56 (p<0.001)
	3	2 (50.0%)	1 (1.6%)	3 (4.6%)
	4	1 (25.0%)	10 (16.4%)	11 (16.9%)
	5	1 (25.0%)	49 (80.3%)	50 (76.9%)
μ ±SD = Mean (standard deviation); M (range) = Median (min:max); Welch = Welch T-Test (not assuming equal variances); OR/RR = odds-ratio / risk-ratio [95% CI] and p value from Fisher test);

0.4 Wash_out_FFH_CEUS

Table 2:

Variable	Details	Da	Nu	Total	Statistics
Wash out FFH CEUS		67 (90.5%)	7 (9.5%)	74
Sex	Feminin	16 (23.9%)	1 (14.3%)	17 (23.0%)	OR=1.88 [0.21, 16.82] (p>0.999)
	Masculin	51 (76.1%)	6 (85.7%)	57 (77.0%)
Varsta	μ ±SD	66.30 ±7.39	63.14 ±9.41	65.54 ±8.33
	M (range)	66 (47:82)	63 (45:75)	66 (44:82)
IMC	μ ±SD	29.38 ±5.97	27.90 ±NA	28.40 ±5.04
	M (range)	29.3 (19.49:38.68)	27.9 (27.9:27.9)	28.35 (19.49:38.68)
APP: fara	Da	25 (37.3%)	4 (57.1%)	29 (39.2%)	OR=0.45 [0.09, 2.16] (p=0.422)
APP: DZ	Da	17 (25.4%)	0	17 (23.0%)	OR=5.20 [0.28, 95.79] (p=0.192)
APP: HTAE	Da	22 (32.8%)	1 (14.3%)	23 (31.1%)	OR=2.93 [0.33, 25.89] (p=0.424)
APP: dislipidemie	Da	0	0	0	OR=0.11 [0.00, 6.02] (p>0.999)
APP: obezitate	Da	7 (10.4%)	1 (14.3%)	8 (10.8%)	OR=0.70 [0.07, 6.69] (p=0.567)
APP: sdr. metabolic	Da	0	0	0	OR=0.11 [0.00, 6.02] (p>0.999)
APP: boala CV	Da	6 (9.0%)	0	6 (8.1%)	OR=1.59 [0.08, 31.05] (p>0.999)
APP oncologice	Da	3 (4.5%)	0	3 (4.1%)	OR=0.81 [0.04, 17.33] (p>0.999)
Dg FFH	HCC cunoscut	14 (21.2%)	1 (14.3%)	15 (20.5%)	V=0.52 (p<0.001)
	HCC de novo	50 (75.8%)	4 (57.1%)	54 (74.0%)
	HCC suspiciune	1 (1.5%)	0	1 (1.4%)
	Formatiune hepatica benigna	1 (1.5%)	0	1 (1.4%)
	Nodul displazic	0	2 (28.6%)	2 (2.7%)
Ciroza hepatica	Da	60 (90.9%)	7 (100%)	67 (91.8%)	OR=0.62 [0.03, 12.15] (p>0.999)
Etiologia CH	Etanolica	23 (34.3%)	2 (28.6%)	25 (33.8%)	V=0.14 (p=0.916)
	VHB	12 (17.9%)	1 (14.3%)	13 (17.6%)
	VHB+VHD	1 (1.5%)	0	1 (1.4%)
	VHC	25 (37.3%)	4 (57.1%)	29 (39.2%)
	Hepatita autoimuna	0	0	0
	NASH	3 (4.5%)	0	3 (4.1%)
	Boala wilson	0	0	0
	Boli colestatice	0	0	0
	Alte etiologii	3 (4.5%)	0	3 (4.1%)
	Etilogie mixta	0	0	0
	Neprecizata	0	0	0
Consum alcool	Da	25 (40.3%)	2 (33.3%)	27 (39.7%)	OR=1.35 [0.23, 7.95] (p>0.999)
Tratament FFH	Da	12 (17.9%)	2 (28.6%)	14 (18.9%)	OR=0.55 [0.09, 3.15] (p=0.611)
Tratament antiviral	Da	19 (28.4%)	3 (42.9%)	22 (29.7%)	OR=0.53 [0.11, 2.58] (p=0.418)
Data tratament antiviral	2013	1 (33.3%)	0 (NA)	1 (33.3%)	V=NA (p>0.999)
	2014-2019	1 (33.3%)	0 (NA)	1 (33.3%)
	2017	1 (33.3%)	0 (NA)	1 (33.3%)
Tip tratament antiviral	1	3 (16.7%)	0	3 (15.0%)	V=0.39 (p=0.546)
	2	2 (11.1%)	1 (50.0%)	3 (15.0%)
	3	6 (33.3%)	1 (50.0%)	7 (35.0%)
	4	6 (33.3%)	0	6 (30.0%)
	5	1 (5.6%)	0	1 (5.0%)
	6	0	0	0
RVS	Da	4 (30.8%)	0	4 (28.6%)	OR=1.42 [0.05, 42.22] (p>0.999)
Ascita	Da	21 (32.8%)	0	21 (29.6%)	OR=7.41 [0.40, 135.95] (p=0.096)
Grad ascita	1	7 (36.8%)	0 (NA)	7 (36.8%)	V=NA (p>0.999)
	2	5 (26.3%)	0 (NA)	5 (26.3%)
	3	7 (36.8%)	0 (NA)	7 (36.8%)
Encefalopatie hepatica	1	60 (92.3%)	6 (100%)	66 (93.0%)	OR=0.85 [0.04, 17.10] (p>0.999)
	2	5 (7.7%)	0	5 (7.0%)
Grad EH	1	3 (60.0%)	0 (NA)	3 (60.0%)	V=NA (p>0.999)
	2	2 (40.0%)	0 (NA)	2 (40.0%)
	3	0	0 (NA)	0
Child 1-child	1	32 (52.5%)	5 (83.3%)	37 (55.2%)	V=0.18 (p=0.335)
	2	24 (39.3%)	1 (16.7%)	25 (37.3%)
	3	5 (8.2%)	0	5 (7.5%)
Puncte Clasa Child	μ ±SD	6.75 ±1.75	5.67 ±0.816	6.58 ±1.83
	M (range)	7 (3:11)	5.5 (5:7)	6 (2:12)
MELD	μ ±SD	11.69 ±4.28	10.17 ±2.56	11.50 ±4.03
	M (range)	11 (5:27)	10 (7:13)	11 (5:27)
MELD Na	μ ±SD	13.30 ±4.54	11.00 ±3.16	13.15 ±4.29
	M (range)	13 (7:27)	10.5 (7:16)	13 (6:27)
BCLC	A	32 (49.2%)	2 (50.0%)	34 (49.3%)	V=0.19 (p=0.478)
	B	14 (21.5%)	2 (50.0%)	16 (23.2%)
	C	16 (24.6%)	0	16 (23.2%)
	D	3 (4.6%)	0	3 (4.3%)
EDS	Da	53 (79.1%)	5 (83.3%)	58 (79.5%)	OR=0.76 [0.08, 7.02] (p>0.999)
VE	Da	39 (70.9%)	3 (60.0%)	42 (70.0%)	OR=1.62 [0.25, 10.66] (p=0.631)
Grad VE	1	14 (38.9%)	1 (33.3%)	15 (38.5%)	V=0.10 (p=0.831)
	2	19 (52.8%)	2 (66.7%)	21 (53.8%)
	3	3 (8.3%)	0	3 (7.7%)
VG	1	51 (96.2%)	5 (100%)	56 (96.6%)	OR=1.87 [0.08, 44.19] (p>0.999)
	2	2 (3.8%)	0	2 (3.4%)
HDS	Da	6 (10.0%)	0	6 (9.2%)	OR=1.31 [0.06, 26.54] (p>0.999)
Aspect ficat US	Cirotic	59 (90.8%)	6 (100%)	65 (91.5%)	OR=0.70 [0.04, 13.98] (p>0.999)
	Noncirotic	6 (9.2%)	0	6 (8.5%)
Nr FFH US	1	35 (60.3%)	4 (57.1%)	39 (60.0%)	V=0.22 (p=0.374)
	2	11 (19.0%)	3 (42.9%)	14 (21.5%)
	3	2 (3.4%)	0	2 (3.1%)
	4	10 (17.2%)	0	10 (15.4%)
Localizare FFH US	μ ±SD	6.30 ±2.07	5.43 ±0.976	6.32 ±2.15
	M (range)	6 (2:11)	5 (4:7)	6 (2:11)
Contur FFH US	Bine delimitat	19 (67.9%)	3 (100%)	22 (71.0%)	OR=0.29 [0.01, 6.27] (p=0.537)
	Cu contur difuz	9 (32.1%)	0	9 (29.0%)
Aspect FFH US	Omogen	8 (19.5%)	3 (50.0%)	11 (23.4%)	V=0.31 (p=0.103)
	Inomogen	31 (75.6%)	2 (33.3%)	33 (70.2%)
	Aspect particular--nodul in nodul	2 (4.9%)	1 (16.7%)	3 (6.4%)
Calcifieri FFH US	Da	2 (3.8%)	0	2 (3.4%)	OR=0.64 [0.03, 14.93] (p>0.999)
Necroza FFH US	Da	8 (15.1%)	0	8 (13.3%)	OR=2.80 [0.15, 53.80] (p=0.578)
Doppler FFH US	Da	20 (40.8%)	3 (50.0%)	23 (41.8%)	OR=0.69 [0.13, 3.77] (p=0.686)
Aspect Doppler FFH US	1	3 (15.8%)	1 (33.3%)	4 (18.2%)	OR=0.38 [0.03, 5.57] (p=0.470)
	2	16 (84.2%)	2 (66.7%)	18 (81.8%)
Dimensiunea1 FFH US	μ ±SD	35.17 ±21.4	33.17 ±15.6	35.55 ±23.2
	M (range)	30 (1.54:90)	34.2 (9:58)	30 (1.54:121)
Dimensiunea2 FFH US	μ ±SD	35.94 ±21.3	34.58 ±20.7	37.87 ±28.5
	M (range)	29.5 (4.35:90)	25.25 (22:75)	29 (1.96:171)
Dimensiunea3 FFH US	μ ±SD	36.68 ±20.6	22.00 ±9.9	35.22 ±20.1
	M (range)	28.2 (17:70)	22 (15:29)	28.2 (15:70)
Tromboza VP US	Da	21 (41.2%)	1 (20.0%)	22 (39.3%)	OR=2.80 [0.29, 26.86] (p=0.638)
Tip Tromboza VP US	Incompleta	6 (46.2%)	1 (100%)	7 (50.0%)	OR=0.29 [0.01, 8.39] (p>0.999)
	Completa	7 (53.8%)	0	7 (50.0%)
Etiologie tromboza VP US	Hematica	3 (25.0%)	1 (100%)	4 (30.8%)	OR=0.12 [0.00, 3.78] (p=0.308)
	Maligna	9 (75.0%)	0	9 (69.2%)
VP US	μ ±SD	16.78 ±15.2	14.07 ±3.72	15.98 ±13.4
	M (range)	13.7 (8:96)	13.65 (10:19)	13.3 (7:96)
Viteza VP US	μ ±SD	21.88 ±11.6	14.43 ±8.24	20.92 ±11.0
	M (range)	18.43 (11:60)	13 (7:23.3)	18.22 (7:60)
VS US	μ ±SD	9.05 ±2.48	8.70 ±4.18	9.03 ±2.71
	M (range)	8.6 (6:15)	10.1 (4:12)	8.8 (4:15)
Splina US	μ ±SD	139.52 ±30.7	150.10 ±24.0	136.34 ±33.8
	M (range)	136 (86:210)	153.5 (110:170)	136 (14:210)
HARI	μ ±SD	0.751 ±0.0791	0.665 ±0.00707	0.746 ±0.0781
	M (range)	0.76 (0.59:0.89)	0.66 (0.66:0.67)	0.75 (0.59:0.89)
SARI	μ ±SD	0.684 ±0.1	0.575 ±0.0495	0.673 ±0.0976
	M (range)	0.71 (0.48:0.89)	0.58 (0.54:0.61)	0.68 (0.48:0.89)
LSM	Da	25 (38.5%)	1 (14.3%)	26 (36.1%)	OR=3.75 [0.43, 33.01] (p=0.410)
Valoare LSM	μ ±SD	41.60 ±51.3	20.50 ±NA	36.84 ±46.4
	M (range)	34.6 (5.3:270)	20.5 (20.5:20.5)	28.9 (5.3:270)
IQR LSM	μ ±SD	4.01 ±3.4	0.30 ±NA	3.51 ±3.27
	M (range)	2.62 (0.5:13.2)	0.3 (0.3:0.3)	1.9 (0.3:13.2)
Elastografie SSM	Da	6 (27.3%)	0	6 (26.1%)	OR=1.18 [0.04, 32.91] (p>0.999)
Valoare SSM	μ ±SD	44.58 ±13.1	35.30 ±NA	47.59 ±15.0
	M (range)	45.4 (21.2:69.44)	35.3 (35.3:35.3)	46.6 (21.2:75.5)
Fibroscan	Da	37 (55.2%)	4 (57.1%)	41 (55.4%)	OR=0.92 [0.19, 4.46] (p>0.999)
Valoare Fibroscan	μ ±SD	32.73 ±24.4	50.16 ±17.1	33.93 ±23.8
	M (range)	24.4 (3.3:75)	54.4 (30:72.1)	29.8 (3.3:75)
CAP	Da	33 (94.3%)	5 (100%)	38 (95.0%)	OR=1.22 [0.05, 28.93] (p>0.999)
Valoare CAP	μ ±SD	252.06 ±72.9	280.00 ±70.9	254.65 ±72.8
	M (range)	256 (100:395)	243 (211:361)	252.5 (100:395)
HVPG	1	34 (51.5%)	2 (33.3%)	36 (50.0%)	OR=2.13 [0.36, 12.41] (p=0.674)
	2	32 (48.5%)	4 (66.7%)	36 (50.0%)
WHVP	μ ±SD	21.63 ±7.74	26.75 ±3.1	23.46 ±12.3
	M (range)	23 (4:44)	26 (24:31)	24 (4:82)
FHVP	μ ±SD	8.70 ±3.88	8.25 ±2.99	8.38 ±3.62
	M (range)	8 (2:22)	8 (5:12)	8 (2:22)
Valoare HVPG	μ ±SD	14.22 ±6.48	18.50 ±4.51	14.51 ±6.54
	M (range)	13 (3:29)	18.5 (13:24)	14 (3:29)
Biopsie FFH	Da	19 (32.8%)	2 (40.0%)	21 (33.3%)	OR=0.73 [0.11, 4.75] (p>0.999)
Biopsie FFH2	Da	19 (32.8%)	1 (20.0%)	20 (31.7%)	OR=1.95 [0.20, 18.65] (p>0.999)
Tip biopsie FFH	percutanata	7 (33.3%)	0	7 (31.8%)	V=0.18 (p=0.696)
	intraoperatrie	2 (9.5%)	0	2 (9.1%)
	piesa de rezectie	12 (57.1%)	1 (100%)	13 (59.1%)
Diagnostic histopat FFH	HCC	20 (95.2%)	1 (100%)	21 (95.5%)	V=0.05 (p=0.823)
	colangiocarcinom	1 (4.8%)	0	1 (4.5%)
	alta leziune maligna	0	0	0
	leziune benigna	0	0	0
	nodul displazic	0	0	0
Histopat HCC grad diferentiere	G1	3 (16.7%)	0	3 (15.8%)	V=0.16 (p=0.784)
	G2	12 (66.7%)	1 (100%)	13 (68.4%)
	G3	3 (16.7%)	0	3 (15.8%)
Histopat HCC Grad Edmontson Steiner	gr1	2 (18.2%)	0	2 (16.7%)	V=0.30 (p=0.580)
	gr2	5 (45.5%)	1 (100%)	6 (50.0%)
	gr3	4 (36.4%)	0	4 (33.3%)
	gr4	0	0	0
	na	0	0	0
Histopat microinvazie vasculara	Da	4 (44.4%)	0	4 (40.0%)	OR=2.45 [0.08, 76.13] (p>0.999)
Histopat margini rezectie	R0	3 (75.0%)	0	3 (60.0%)	OR=7.00 [0.17, 291.34] (p=0.400)
	R1	1 (25.0%)	1 (100%)	2 (40.0%)
Metastaze intraoperator	Da	2 (66.7%)	0 (NA)	2 (66.7%)	OR=1.67 [0.02, 137.35] (p>0.999)
CT	Da	51 (76.1%)	3 (42.9%)	54 (73.0%)	OR=4.25 [0.86, 21.03] (p=0.080)
Substanta contrast CT	Da	46 (100%)	2 (100%)	48 (100%)	OR=18.60 [0.30, 1 146.48] (p>0.999)
LiRADS CT	?	1 (2.3%)	0	1 (2.1%)	V=0.57 (p=0.002)
	3	0	1 (33.3%)	1 (2.1%)
	4	1 (2.3%)	0	1 (2.1%)
	5	42 (95.5%)	2 (66.7%)	44 (93.6%)
Nr FFH CT	1	23 (57.5%)	2 (100%)	25 (59.5%)	V=0.18 (p=0.490)
	2	5 (12.5%)	0	5 (11.9%)
	3	12 (30.0%)	0	12 (28.6%)
Metastaze CT	Da	1 (50.0%)	0 (NA)	1 (50.0%)	OR=1.00 [0.01, 92.42] (p>0.999)
Ciroza CT	Da	40 (90.9%)	3 (100%)	43 (91.5%)	OR=1.29 [0.06, 29.09] (p>0.999)
RMN	Da	19 (30.2%)	6 (85.7%)	25 (35.7%)	OR=0.07 [0.01, 0.64] (p=0.007)
LiRADS RMN	3	2 (12.5%)	0	2 (9.5%)	V=0.18 (p=0.706)
	4	3 (18.8%)	1 (20.0%)	4 (19.0%)
	5	11 (68.8%)	4 (80.0%)	15 (71.4%)
Nr FFH RMN	?	0	0	0	V=0.21 (p=0.637)
	1	7 (43.8%)	2 (50.0%)	9 (45.0%)
	2	6 (37.5%)	2 (50.0%)	8 (40.0%)
	3	3 (18.8%)	0	3 (15.0%)
Ciroza RMN	Da	13 (92.9%)	5 (100%)	18 (94.7%)	OR=0.82 [0.03, 23.34] (p>0.999)
Tipul interventiei 1	1	2 (7.7%)	0	2 (6.7%)	V=0.23 (p=0.656)
	2	12 (46.2%)	1 (25.0%)	13 (43.3%)
	3	6 (23.1%)	1 (25.0%)	7 (23.3%)
	4	0	0	0
	5	6 (23.1%)	2 (50.0%)	8 (26.7%)
Tip interventie nr 2	3	1 (33.3%)	0 (NA)	1 (33.3%)	V=NA (p>0.999)
	4	1 (33.3%)	0 (NA)	1 (33.3%)
	5	1 (33.3%)	0 (NA)	1 (33.3%)
Deces	Da	29 (43.9%)	2 (28.6%)	31 (42.5%)	OR=1.96 [0.35, 10.84] (p=0.691)
AFP	μ ±SD	139.31 ±168.6	91.00 ±152.5	130.75 ±164.0
	M (range)	37.8 (2.2:412.8)	12 (4.6:400)	32.5 (2.2:412.8)
Hg	μ ±SD	13.48 ±2.05	14.03 ±2.4	13.35 ±2.27
	M (range)	13.7 (8.2:17.9)	14.5 (9:16.1)	13.7 (7.6:18)
PTL	μ ±SD	123.90 ±71.4	123.57 ±53.0	131.70 ±78.0
	M (range)	99 (26:428)	124 (39:217)	104 (26:428)
GOT	μ ±SD	60.91 ±34.3	41.71 ±30.0	58.95 ±35.6
	M (range)	51 (4:150)	36 (20:108)	47.5 (4:153)
GPT	μ ±SD	47.90 ±33.7	34.14 ±39.0	44.26 ±31.6
	M (range)	37 (13:182)	21 (7:121)	35.5 (7:182)
BT	μ ±SD	2.08 ±3.21	4.00 ±6.64	3.02 ±9.21
	M (range)	1.4 (0.3:26)	1.6 (0.6:19)	1.4 (0.3:85)
BD	μ ±SD	5.15 ±34.7	0.903 ±0.498	4.58 ±30.1
	M (range)	0.74 (0.07:285)	0.84 (0.33:1.82)	0.74 (0.07:285)
GGT	μ ±SD	149.38 ±137.0	77.29 ±47.1	137.01 ±124.0
	M (range)	98.5 (12:616)	70 (17:151)	96 (12:616)
FA	μ ±SD	362.89 ±229.5	277.14 ±61.8	355.79 ±219.7
	M (range)	305 (4.8:1244)	279 (200:352)	305 (4.8:1244)
ALB	μ ±SD	4.00 ±2.57	8.39 ±12.2	4.93 ±5.96
	M (range)	3.75 (2.5:24)	3.8 (3.5:36)	3.7 (2.5:36)
INR	μ ±SD	1.28 ±0.318	1.28 ±0.178	1.28 ±0.283
	M (range)	1.27 (0.39:3.03)	1.25 (1.02:1.51)	1.26 (0.39:3.03)
COL	μ ±SD	157.07 ±42.2	168.00 ±101.5	157.96 ±55.3
	M (range)	149 (83:310)	136 (92:369)	147 (1.93:369)
TG	μ ±SD	93.74 ±43.6	100.80 ±34.3	100.10 ±47.8
	M (range)	80 (45:272)	89 (77:161)	89.5 (45:297)
Fe	μ ±SD	91.96 ±51.1	133.83 ±54.9	98.00 ±54.5
	M (range)	80 (14:257)	108.5 (82:228)	85.5 (14:257)
Crea	μ ±SD	0.90 ±0.364	0.857 ±0.202	0.90 ±0.334
	M (range)	0.86 (0.05:2.35)	0.89 (0.6:1.08)	0.85 (0.05:2.35)
Uree	μ ±SD	41.67 ±21.4	30.86 ±8.51	42.59 ±26.1
	M (range)	37 (17:149)	29 (22:48)	36 (0.92:189)
Na	μ ±SD	138.25 ±4.0	140.71 ±3.73	138.43 ±3.94
	M (range)	139 (123:146)	140 (137:146)	139 (123:146)
Glicemie	μ ±SD	124.96 ±42.1	103.75 ±20.8	121.23 ±38.7
	M (range)	116 (60:291)	96.15 (88:144.2)	112 (60:291)
Sange stocat	Da	3 (33.3%)	0	3 (30.0%)	OR=1.62 [0.05, 51.11] (p>0.999)
CEUS	Da	67 (100%)	7 (100%)	74 (100%)	OR=9.00 [0.17, 487.40] (p>0.999)
Tip APHE CEUS	Izocaptanta	5 (7.5%)	1 (14.3%)	6 (8.1%)	OR=0.48 [0.05, 4.85] (p=0.461)
	Hipercaptanta	62 (92.5%)	6 (85.7%)	68 (91.9%)
Caracterizare APHE CEUS	Inomogen	8 (61.5%)	0 (NA)	8 (61.5%)	OR=1.55 [0.03, 89.96] (p>0.999)
	Omogen	5 (38.5%)	0 (NA)	5 (38.5%)
Viteza APHE CEUS	Lent impreuna cu parenchimul	2 (16.7%)	0 (NA)	2 (16.7%)	OR=0.24 [0.00, 15.19] (p>0.999)
	Rapid, intens	10 (83.3%)	0 (NA)	10 (83.3%)
Tip wash out FFH CEUS	Precoce	5 (7.6%)	0 (NA)	5 (7.6%)	OR=0.09 [0.00, 4.96] (p>0.999)
	Tardiv	61 (92.4%)	0 (NA)	61 (92.4%)
LiRADS CEUS	2	0	0	0	V=0.48 (p<0.001)
	3	2 (3.5%)	1 (16.7%)	3 (4.8%)
	4	7 (12.3%)	4 (66.7%)	11 (17.5%)
	5	48 (84.2%)	1 (16.7%)	49 (77.8%)
μ ±SD = Mean (standard deviation); M (range) = Median (min:max); Welch = Welch T-Test (not assuming equal variances); OR/RR = odds-ratio / risk-ratio [95% CI] and p value from Fisher test);

0.5 BCLC

Table 3:

Variable	Details	A	B	C	D	Total	Statistics
BCLC		35 (40.7%)	21 (24.4%)	25 (29.1%)	5 (5.8%)	86
Sex	Feminin	9 (25.7%)	4 (19.0%)	4 (16.0%)	1 (20.0%)	18 (20.9%)	V=0.10 (p=0.826)
	Masculin	26 (74.3%)	17 (81.0%)	21 (84.0%)	4 (80.0%)	68 (79.1%)
Varsta	μ ±SD	65.54 ±5.96	62.43 ±9.51	64.84 ±8.58	70.40 ±12.4	65.54 ±8.33
	M (range)	64 (51:77)	65 (44:77)	63 (47:78)	78 (51:80)	66 (44:82)
IMC	μ ±SD	29.78 ±8.15	27.75 ±4.04	27.65 ±1.23		28.40 ±5.04
	M (range)	30.48 (19.49:38.68)	29.3 (20.86:31.18)	28.31 (26.23:28.4)		28.35 (19.49:38.68)
APP: fara	Da	10 (28.6%)	4 (19.0%)	13 (52.0%)	2 (40.0%)	29 (33.7%)	V=0.27 (p=0.099)
APP: DZ	Da	11 (31.4%)	6 (28.6%)	7 (28.0%)	1 (20.0%)	25 (29.1%)	V=0.06 (p=0.958)
APP: HTAE	Da	15 (42.9%)	6 (28.6%)	3 (12.0%)	2 (40.0%)	26 (30.2%)	V=0.28 (p=0.077)
APP: dislipidemie	Da	0	0	0	0	0	V=NA (p>0.999)
APP: obezitate	Da	7 (20.0%)	1 (4.8%)	1 (4.0%)	0	9 (10.5%)	V=0.26 (p=0.120)
APP: sdr. metabolic	Da	0	0	0	0	0	V=NA (p>0.999)
APP: boala CV	Da	2 (5.7%)	4 (19.0%)	2 (8.0%)	0	8 (9.3%)	V=0.20 (p=0.326)
APP oncologice	Da	1 (2.9%)	2 (9.5%)	3 (12.0%)	0	6 (7.0%)	V=0.17 (p=0.480)
Dg FFH	HCC cunoscut	10 (29.4%)	8 (38.1%)	6 (24.0%)	2 (40.0%)	26 (30.6%)	V=0.16 (p=0.653)
	HCC de novo	24 (70.6%)	12 (57.1%)	18 (72.0%)	3 (60.0%)	57 (67.1%)
	HCC suspiciune	0	1 (4.8%)	0	0	1 (1.2%)
	Formatiune hepatica benigna	0	0	0	0	0
	Nodul displazic	0	0	1 (4.0%)	0	1 (1.2%)
Ciroza hepatica	Da	32 (91.4%)	18 (85.7%)	22 (91.7%)	5 (100%)	77 (90.6%)	V=0.12 (p=0.761)
Etiologia CH	Etanolica	10 (28.6%)	6 (28.6%)	14 (56.0%)	2 (40.0%)	32 (37.2%)	V=0.21 (p=0.758)
	VHB	7 (20.0%)	4 (19.0%)	2 (8.0%)	1 (20.0%)	14 (16.3%)
	VHB+VHD	1 (2.9%)	0	0	0	1 (1.2%)
	VHC	14 (40.0%)	8 (38.1%)	7 (28.0%)	1 (20.0%)	30 (34.9%)
	Hepatita autoimuna	0	0	0	0	0
	NASH	1 (2.9%)	2 (9.5%)	1 (4.0%)	0	4 (4.7%)
	Boala wilson	0	0	0	0	0
	Boli colestatice	0	0	0	0	0
	Alte etiologii	2 (5.7%)	1 (4.8%)	1 (4.0%)	1 (20.0%)	5 (5.8%)
	Etilogie mixta	0	0	0	0	0
	Neprecizata	0	0	0	0	0
Consum alcool	Da	12 (34.3%)	5 (26.3%)	14 (73.7%)	2 (40.0%)	33 (42.3%)	V=0.37 (p=0.014)
Tratament FFH	Da	7 (20.0%)	4 (19.0%)	4 (16.0%)	1 (20.0%)	16 (18.6%)	V=0.04 (p=0.983)
Tratament antiviral	Da	9 (25.7%)	4 (19.0%)	6 (24.0%)	0	19 (22.1%)	V=0.15 (p=0.604)
Data tratament antiviral	2013	1 (100%)	0	0	0 (NA)	1 (33.3%)	V=>0.99 (p=0.199)
	2014-2019	0	1 (100%)	0	0 (NA)	1 (33.3%)
	2017	0	0	1 (100%)	0 (NA)	1 (33.3%)
Tip tratament antiviral	1	3 (25.0%)	0	0	0 (NA)	3 (15.8%)	V=0.38 (p=0.852)
	2	1 (8.3%)	1 (25.0%)	1 (33.3%)	0 (NA)	3 (15.8%)
	3	4 (33.3%)	1 (25.0%)	1 (33.3%)	0 (NA)	6 (31.6%)
	4	2 (16.7%)	2 (50.0%)	1 (33.3%)	0 (NA)	5 (26.3%)
	5	1 (8.3%)	0	0	0 (NA)	1 (5.3%)
	6	1 (8.3%)	0	0	0 (NA)	1 (5.3%)
RVS	Da	2 (28.6%)	0	2 (50.0%)	0 (NA)	4 (30.8%)	V=0.35 (p=0.450)
Ascita	Da	8 (22.9%)	5 (23.8%)	9 (40.9%)	4 (80.0%)	26 (31.3%)	V=0.31 (p=0.043)
Grad ascita	1	3 (42.9%)	2 (40.0%)	1 (14.3%)	1 (25.0%)	7 (30.4%)	V=0.33 (p=0.533)
	2	1 (14.3%)	0	3 (42.9%)	2 (50.0%)	6 (26.1%)
	3	3 (42.9%)	3 (60.0%)	3 (42.9%)	1 (25.0%)	10 (43.5%)
Encefalopatie hepatica	1	33 (97.1%)	21 (100%)	21 (87.5%)	3 (60.0%)	78 (92.9%)	V=0.37 (p=0.008)
	2	1 (2.9%)	0	3 (12.5%)	2 (40.0%)	6 (7.1%)
Grad EH	1	1 (100%)	0 (NA)	2 (66.7%)	0	3 (50.0%)	V=0.59 (p=0.384)
	2	0	0 (NA)	1 (33.3%)	1 (50.0%)	2 (33.3%)
	3	0	0 (NA)	0	1 (50.0%)	1 (16.7%)
Child 1-child	1	19 (59.4%)	10 (55.6%)	11 (50.0%)	0	40 (51.9%)	V=0.28 (p=0.061)
	2	11 (34.4%)	8 (44.4%)	9 (40.9%)	3 (60.0%)	31 (40.3%)
	3	2 (6.2%)	0	2 (9.1%)	2 (40.0%)	6 (7.8%)
Puncte Clasa Child	μ ±SD	6.39 ±1.75	6.12 ±1.62	6.93 ±1.71	9.20 ±2.28	6.58 ±1.83
	M (range)	6 (3:10)	6 (2:9)	7 (5:10)	9 (7:12)	6 (2:12)
MELD	μ ±SD	11.56 ±3.89	11.72 ±3.14	11.55 ±4.71	13.60 ±5.59	11.50 ±4.03
	M (range)	11 (7:22)	11 (7:20)	11 (5:27)	12 (9:23)	11 (5:27)
MELD Na	μ ±SD	13.13 ±4.46	12.44 ±3.03	14.53 ±4.82	15.40 ±4.39	13.15 ±4.29
	M (range)	12.5 (7:24)	12.5 (7:20)	15 (8:27)	14 (12:23)	13 (6:27)
EDS	Da	30 (85.7%)	14 (66.7%)	16 (64.0%)	5 (100%)	65 (75.6%)	V=0.27 (p=0.099)
VE	Da	21 (70.0%)	11 (73.3%)	14 (77.8%)	4 (80.0%)	50 (73.5%)	V=0.08 (p=0.926)
Grad VE	1	5 (26.3%)	7 (70.0%)	6 (42.9%)	2 (50.0%)	20 (42.6%)	V=0.28 (p=0.299)
	2	12 (63.2%)	3 (30.0%)	7 (50.0%)	1 (25.0%)	23 (48.9%)
	3	2 (10.5%)	0	1 (7.1%)	1 (25.0%)	4 (8.5%)
VG	1	29 (100%)	14 (100%)	16 (88.9%)	5 (100%)	64 (97.0%)	V=0.29 (p=0.139)
	2	0	0	2 (11.1%)	0	2 (3.0%)
HDS	Da	3 (8.8%)	1 (5.3%)	5 (29.4%)	0	9 (12.0%)	V=0.30 (p=0.082)
Aspect ficat US	Cirotic	31 (93.9%)	16 (76.2%)	23 (95.8%)	4 (80.0%)	74 (89.2%)	V=0.27 (p=0.113)
	Noncirotic	2 (6.1%)	5 (23.8%)	1 (4.2%)	1 (20.0%)	9 (10.8%)
Nr FFH US	1	26 (83.9%)	10 (50.0%)	7 (38.9%)	0	43 (58.9%)	V=0.40 (p<0.001)
	2	5 (16.1%)	5 (25.0%)	3 (16.7%)	0	13 (17.8%)
	3	0	2 (10.0%)	1 (5.6%)	0	3 (4.1%)
	4	0	3 (15.0%)	7 (38.9%)	4 (100%)	14 (19.2%)
Localizare FFH US	μ ±SD	5.79 ±1.83	6.57 ±2.2	6.78 ±2.33	8.80 ±2.39	6.32 ±2.15
	M (range)	6 (2:9)	7 (2.3:10)	6 (3.8:11)	10 (5:11)	6 (2:11)
Contur FFH US	Bine delimitat	15 (83.3%)	8 (72.7%)	3 (50.0%)	0	26 (70.3%)	V=0.45 (p=0.060)
	Cu contur difuz	3 (16.7%)	3 (27.3%)	3 (50.0%)	2 (100%)	11 (29.7%)
Aspect FFH US	Omogen	7 (29.2%)	0	1 (8.3%)	0	8 (16.3%)	V=0.25 (p=0.386)
	Inomogen	16 (66.7%)	10 (90.9%)	10 (83.3%)	2 (100%)	38 (77.6%)
	Aspect particular--nodul in nodul	1 (4.2%)	1 (9.1%)	1 (8.3%)	0	3 (6.1%)
Calcifieri FFH US	Da	1 (3.4%)	0	2 (13.3%)	0	3 (4.5%)	V=0.24 (p=0.284)
Necroza FFH US	Da	3 (10.3%)	3 (16.7%)	3 (18.8%)	0	9 (13.2%)	V=0.15 (p=0.663)
Doppler FFH US	Da	6 (24.0%)	11 (68.8%)	7 (38.9%)	2 (66.7%)	26 (41.9%)	V=0.38 (p=0.031)
Aspect Doppler FFH US	1	1 (20.0%)	2 (18.2%)	0	0	3 (12.0%)	V=0.28 (p=0.587)
	2	4 (80.0%)	9 (81.8%)	7 (100%)	2 (100%)	22 (88.0%)
Dimensiunea1 FFH US	μ ±SD	27.04 ±13.7	50.43 ±29.6	44.00 ±23.4	26.99 ±25.1	35.55 ±23.2
	M (range)	26 (1.54:75)	46.5 (6:121)	47.5 (8:77)	14.8 (2.86:60)	30 (1.54:121)
Dimensiunea2 FFH US	μ ±SD	26.96 ±12.8	53.67 ±37.5	53.29 ±30.1	22.35 ±23.2	37.87 ±28.5
	M (range)	23.1 (4.35:67)	43 (20:171)	64 (6:90)	17.5 (1.96:47.6)	29 (1.96:171)
Dimensiunea3 FFH US	μ ±SD	28.16 ±15.4	36.50 ±18.9	66.00 ±3.61		35.22 ±20.1
	M (range)	26 (17:67)	33 (17:70)	65 (63:70)		28.2 (15:70)
Tromboza VP US	Da	6 (25.0%)	4 (25.0%)	15 (78.9%)	3 (75.0%)	28 (44.4%)	V=0.52 (p<0.001)
Tip Tromboza VP US	Incompleta	4 (100%)	1 (100%)	4 (40.0%)	0	9 (52.9%)	V=0.66 (p=0.061)
	Completa	0	0	6 (60.0%)	2 (100%)	8 (47.1%)
Etiologie tromboza VP US	Hematica	4 (80.0%)	0	2 (22.2%)	0	6 (33.3%)	V=0.64 (p=0.060)
	Maligna	1 (20.0%)	1 (100%)	7 (77.8%)	3 (100%)	12 (66.7%)
VP US	μ ±SD	13.38 ±3.0	14.76 ±3.23	17.62 ±7.89	14.90 ±4.1	15.98 ±13.4
	M (range)	12.6 (8:22)	14 (10:21)	15.75 (11:28)	14.9 (12:17.8)	13.3 (7:96)
Viteza VP US	μ ±SD	19.78 ±7.01	13.00 ±6.0	26.80 ±19.9	23.00 ±NA	20.92 ±11.0
	M (range)	18 (12:33)	13 (7:19)	18 (11:60)	23 (23:23)	18.22 (7:60)
VS US	μ ±SD	8.86 ±2.55	11.00 ±2.55	11.00 ±NA	7.25 ±1.91	9.03 ±2.71
	M (range)	8.1 (6:14.1)	10 (9:15)	11 (11:11)	7.25 (5.9:8.6)	8.8 (4:15)
Splina US	μ ±SD	142.94 ±34.0	132.73 ±45.3	134.00 ±29.4	131.03 ±1.79	136.34 ±33.8
	M (range)	136 (86:210)	145 (14:195.9)	140 (95:198)	130 (130:133.1)	136 (14:210)
HARI	μ ±SD	0.739 ±0.0899	0.752 ±0.0471	0.76 ±0.0447	0.743 ±0.134	0.746 ±0.0781
	M (range)	0.74 (0.6:0.89)	0.76 (0.67:0.81)	0.76 (0.7:0.81)	0.8 (0.59:0.84)	0.75 (0.59:0.89)
SARI	μ ±SD	0.679 ±0.101	0.67 ±0.089	0.634 ±0.068	0.76 ±0.115	0.673 ±0.0976
	M (range)	0.71 (0.48:0.89)	0.68 (0.58:0.77)	0.64 (0.56:0.71)	0.72 (0.67:0.89)	0.68 (0.48:0.89)
LSM	Da	15 (44.1%)	7 (33.3%)	4 (16.7%)	3 (60.0%)	29 (34.5%)	V=0.27 (p=0.101)
Valoare LSM	μ ±SD	40.26 ±63.6	33.64 ±18.1	45.60 ±21.6	43.30 ±0.283	36.84 ±46.4
	M (range)	20.35 (5.3:270)	37.5 (5.3:61.7)	41.05 (25.3:75)	43.3 (43.1:43.5)	28.9 (5.3:270)
IQR LSM	μ ±SD	3.65 ±2.84	3.99 ±5.02	1.73 ±1.57	3.95 ±2.05	3.51 ±3.27
	M (range)	2.32 (0.5:7.9)	1.75 (0.3:13.2)	1.2 (0.5:3.5)	3.95 (2.5:5.4)	1.9 (0.3:13.2)
Elastografie SSM	Da	4 (30.8%)	1 (20.0%)	0	2 (66.7%)	7 (22.6%)	V=0.47 (p=0.080)
Valoare SSM	μ ±SD	45.52 ±15.5	43.35 ±7.85	58.30 ±16.4	57.75 ±25.1	47.59 ±15.0
	M (range)	48.95 (21.2:69.44)	42.65 (35.3:52.8)	58.3 (46.7:69.9)	57.75 (40:75.5)	46.6 (21.2:75.5)
Fibroscan	Da	22 (62.9%)	15 (71.4%)	9 (36.0%)	3 (60.0%)	49 (57.0%)	V=0.28 (p=0.079)
Valoare Fibroscan	μ ±SD	26.59 ±17.3	38.20 ±26.6	43.39 ±29.4	43.80 ±29.1	33.93 ±23.8
	M (range)	21.6 (6.1:75)	34.3 (3.3:75)	52.8 (9.2:75)	39.1 (17.3:75)	29.8 (3.3:75)
CAP	Da	19 (95.0%)	14 (93.3%)	9 (100%)	2 (100%)	44 (95.7%)	V=0.12 (p=0.870)
Valoare CAP	μ ±SD	259.58 ±67.7	255.14 ±83.4	233.44 ±71.1	243.00 ±39.6	254.65 ±72.8
	M (range)	256 (100:395)	272.5 (100:363)	246 (100:361)	243 (215:271)	252.5 (100:395)
HVPG	1	9 (27.3%)	13 (61.9%)	19 (76.0%)	5 (100%)	46 (54.8%)	V=0.48 (p<0.001)
	2	24 (72.7%)	8 (38.1%)	6 (24.0%)	0	38 (45.2%)
WHVP	μ ±SD	21.09 ±5.97	29.44 ±21.2	25.80 ±12.5		23.46 ±12.3
	M (range)	23 (4:29)	24 (11:82)	27 (11:44)		24 (4:82)
FHVP	μ ±SD	8.83 ±3.19	7.22 ±1.2	9.20 ±7.5		8.38 ±3.62
	M (range)	9 (2:17)	7 (5:9)	7 (3:22)		8 (2:22)
Valoare HVPG	μ ±SD	13.54 ±5.62	15.56 ±8.28	17.83 ±6.88		14.51 ±6.54
	M (range)	13 (3:27)	15 (3:29)	20 (8:24)		14 (3:29)
Biopsie FFH	Da	12 (36.4%)	8 (44.4%)	5 (31.2%)	1 (20.0%)	26 (36.1%)	V=0.13 (p=0.736)
Biopsie FFH2	Da	12 (36.4%)	8 (44.4%)	5 (31.2%)	1 (20.0%)	26 (36.1%)	V=0.13 (p=0.736)
Tip biopsie FFH	percutanata	3 (23.1%)	2 (28.6%)	4 (80.0%)	0	9 (34.6%)	V=0.41 (p=0.191)
	intraoperatrie	1 (7.7%)	2 (28.6%)	0	0	3 (11.5%)
	piesa de rezectie	9 (69.2%)	3 (42.9%)	1 (20.0%)	1 (100%)	14 (53.8%)
Diagnostic histopat FFH	HCC	13 (100%)	7 (100%)	3 (60.0%)	1 (100%)	24 (92.3%)	V=0.42 (p=0.168)
	colangiocarcinom	0	0	1 (20.0%)	0	1 (3.8%)
	alta leziune maligna	0	0	0	0	0
	leziune benigna	0	0	1 (20.0%)	0	1 (3.8%)
	nodul displazic	0	0	0	0	0
Histopat HCC grad diferentiere	G1	1 (9.1%)	0	2 (50.0%)	0 (NA)	3 (14.3%)	V=0.38 (p=0.190)
	G2	8 (72.7%)	4 (66.7%)	1 (25.0%)	0 (NA)	13 (61.9%)
	G3	2 (18.2%)	2 (33.3%)	1 (25.0%)	0 (NA)	5 (23.8%)
Histopat HCC Grad Edmontson Steiner	gr1	1 (12.5%)	0	1 (33.3%)	0	2 (14.3%)	V=0.31 (p=0.843)
	gr2	4 (50.0%)	1 (50.0%)	1 (33.3%)	0	6 (42.9%)
	gr3	3 (37.5%)	1 (50.0%)	1 (33.3%)	1 (100%)	6 (42.9%)
	gr4	0	0	0	0	0
	na	0	0	0	0	0
Histopat microinvazie vasculara	Da	2 (25.0%)	2 (100%)	1 (100%)	0 (NA)	5 (45.5%)	V=0.67 (p=0.084)
Histopat margini rezectie	R0	2 (50.0%)	0 (NA)	1 (100%)	0 (NA)	3 (60.0%)	V=0.41 (p=0.361)
	R1	2 (50.0%)	0 (NA)	0	0 (NA)	2 (40.0%)
Metastaze intraoperator	Da	2 (100%)	0 (NA)	0	0 (NA)	2 (66.7%)	V=>0.99 (p=0.083)
CT	Da	25 (71.4%)	15 (71.4%)	21 (84.0%)	3 (60.0%)	64 (74.4%)	V=0.15 (p=0.569)
Substanta contrast CT	Da	21 (100%)	13 (92.9%)	19 (100%)	3 (100%)	56 (98.2%)	V=0.23 (p=0.373)
LiRADS CT	?	0	1 (7.7%)	0	0	1 (1.8%)	V=0.20 (p=0.641)
	3	0	0	1 (5.0%)	0	1 (1.8%)
	4	1 (4.8%)	0	0	0	1 (1.8%)
	5	20 (95.2%)	12 (92.3%)	19 (95.0%)	3 (100%)	54 (94.7%)
Nr FFH CT	1	15 (88.2%)	7 (58.3%)	7 (35.0%)	0	29 (55.8%)	V=0.44 (p=0.003)
	2	2 (11.8%)	2 (16.7%)	2 (10.0%)	0	6 (11.5%)
	3	0	3 (25.0%)	11 (55.0%)	3 (100%)	17 (32.7%)
Metastaze CT	Da	1 (50.0%)	0 (NA)	0 (NA)	0 (NA)	1 (50.0%)	V=NA (p>0.999)
Ciroza CT	Da	20 (95.2%)	11 (84.6%)	19 (100%)	3 (100%)	53 (94.6%)	V=0.26 (p=0.279)
RMN	Da	13 (38.2%)	6 (33.3%)	7 (28.0%)	0	26 (31.7%)	V=0.20 (p=0.366)
LiRADS RMN	3	1 (8.3%)	0	0	0 (NA)	1 (4.8%)	V=0.30 (p=0.447)
	4	3 (25.0%)	0	0	0 (NA)	3 (14.3%)
	5	8 (66.7%)	5 (100%)	4 (100%)	0 (NA)	17 (81.0%)
Nr FFH RMN	?	0	0	1 (25.0%)	0 (NA)	1 (5.0%)	V=0.55 (p=0.055)
	1	5 (45.5%)	0	2 (50.0%)	0 (NA)	7 (35.0%)
	2	5 (45.5%)	5 (100%)	0	0 (NA)	10 (50.0%)
	3	1 (9.1%)	0	1 (25.0%)	0 (NA)	2 (10.0%)
Ciroza RMN	Da	9 (90.0%)	5 (83.3%)	4 (100%)	0 (NA)	18 (90.0%)	V=0.19 (p=0.690)
Tipul interventiei 1	1	0	1 (11.1%)	1 (50.0%)	0 (NA)	2 (6.5%)	V=0.49 (p=0.021)
	2	9 (45.0%)	3 (33.3%)	1 (50.0%)	0 (NA)	13 (41.9%)
	3	7 (35.0%)	0	0	0 (NA)	7 (22.6%)
	4	0	0	0	0 (NA)	0
	5	4 (20.0%)	5 (55.6%)	0	0 (NA)	9 (29.0%)
Tip interventie nr 2	3	1 (33.3%)	0 (NA)	0 (NA)	0 (NA)	1 (33.3%)	V=NA (p>0.999)
	4	1 (33.3%)	0 (NA)	0 (NA)	0 (NA)	1 (33.3%)
	5	1 (33.3%)	0 (NA)	0 (NA)	0 (NA)	1 (33.3%)
Deces	Da	9 (25.7%)	11 (52.4%)	18 (75.0%)	5 (100%)	43 (50.6%)	V=0.48 (p<0.001)
AFP	μ ±SD	80.37 ±130.8	170.11 ±177.5	174.63 ±179.3	288.08 ±159.2	130.75 ±164.0
	M (range)	11.55 (2.2:401.6)	77.65 (5.5:400)	40 (3.6:400)	400 (109.9:412.8)	32.5 (2.2:412.8)
Hg	μ ±SD	13.59 ±2.26	13.64 ±2.08	13.37 ±2.13	11.00 ±2.23	13.35 ±2.27
	M (range)	13.7 (8.2:17.9)	13.3 (9.3:18)	13.8 (8.4:16.8)	11.1 (7.6:13.4)	13.7 (7.6:18)
PTL	μ ±SD	116.69 ±62.9	141.24 ±97.8	140.04 ±85.2	144.80 ±67.4	131.70 ±78.0
	M (range)	92 (26:288)	95 (39:366)	121 (45:428)	170 (40:216)	104 (26:428)
GOT	μ ±SD	49.49 ±29.9	56.38 ±27.5	72.46 ±37.7	117.40 ±32.6	58.95 ±35.6
	M (range)	43 (4:147)	45 (26:125)	61.5 (14:151)	104 (79:153)	47.5 (4:153)
GPT	μ ±SD	45.20 ±37.0	47.52 ±25.6	48.12 ±31.8	44.00 ±22.8	44.26 ±31.6
	M (range)	35 (13:182)	37 (17:121)	40.5 (13:130)	35 (24:83)	35.5 (7:182)
BT	μ ±SD	1.65 ±1.1	1.55 ±1.33	6.09 ±17.2	2.76 ±2.54	3.02 ±9.21
	M (range)	1.2 (0.5:5.7)	1.3 (0.3:6.3)	1.8 (0.3:85)	1.9 (0.7:7.2)	1.4 (0.3:85)
BD	μ ±SD	8.92 ±48.0	0.875 ±1.04	3.11 ±10.6	2.07 ±1.95	4.58 ±30.1
	M (range)	0.72 (0.22:285)	0.66 (0.13:5)	0.94 (0.07:54)	1.46 (0.43:5.46)	0.74 (0.07:285)
GGT	μ ±SD	109.97 ±119.9	147.86 ±134.2	178.08 ±118.1	217.00 ±117.9	137.01 ±124.0
	M (range)	70 (12:586)	102 (25:616)	140.5 (31:542)	257 (62:365)	96 (12:616)
FA	μ ±SD	306.97 ±157.0	353.67 ±238.8	445.47 ±275.1	467.00 ±137.8	355.79 ±219.7
	M (range)	268 (13:691)	277 (175:1119)	379 (4.8:1244)	447 (307:678)	305 (4.8:1244)
ALB	μ ±SD	4.31 ±3.53	6.77 ±9.09	4.87 ±6.51	2.86 ±0.428	4.93 ±5.96
	M (range)	3.8 (2.5:24)	4 (2.5:36)	3.5 (2.8:36)	2.6 (2.5:3.5)	3.7 (2.5:36)
INR	μ ±SD	1.30 ±0.394	1.23 ±0.156	1.30 ±0.208	1.29 ±0.154	1.28 ±0.283
	M (range)	1.26 (0.39:3.03)	1.23 (1:1.45)	1.3 (0.95:1.7)	1.32 (1.11:1.52)	1.26 (0.39:3.03)
COL	μ ±SD	141.73 ±72.9	164.80 ±31.4	156.59 ±38.6	217.00 ±131.5	157.96 ±55.3
	M (range)	124 (1.93:369)	166 (113:228)	142 (109:246)	217 (124:310)	147 (1.93:369)
TG	μ ±SD	87.94 ±35.9	106.33 ±58.0	92.41 ±28.9	119.00 ±17.0	100.10 ±47.8
	M (range)	86 (45:171)	89 (45:272)	82 (50:140)	119 (107:131)	89.5 (45:297)
Fe	μ ±SD	95.88 ±58.2	103.79 ±59.9	96.61 ±53.7	78.00 ±40.9	98.00 ±54.5
	M (range)	87 (14:257)	84 (30:228)	84.5 (23:213)	68 (43:123)	85.5 (14:257)
Crea	μ ±SD	0.884 ±0.277	0.904 ±0.286	0.925 ±0.44	1.12 ±0.462	0.90 ±0.334
	M (range)	0.86 (0.38:1.89)	0.89 (0.49:1.59)	0.82 (0.05:2.35)	0.96 (0.8:1.93)	0.85 (0.05:2.35)
Uree	μ ±SD	41.66 ±18.9	40.62 ±19.5	47.29 ±40.0	46.98 ±30.3	42.59 ±26.1
	M (range)	34 (20:100)	37 (19:111)	34.5 (17:189)	65 (0.92:70)	36 (0.92:189)
Na	μ ±SD	138.89 ±3.53	139.38 ±2.78	136.38 ±4.7	138.40 ±4.39	138.43 ±3.94
	M (range)	139 (128:145)	139 (135:146)	137.5 (123:142)	139 (132:144)	139 (123:146)
Glicemie	μ ±SD	129.66 ±48.9	116.39 ±27.0	119.72 ±32.0	90.88 ±17.4	121.23 ±38.7
	M (range)	118.2 (72:291)	107.1 (76:176.5)	113.1 (67:191)	97.5 (60:101)	112 (60:291)
Sange stocat	Da	1 (100%)	1 (50.0%)	2 (22.2%)	0	4 (30.8%)	V=0.51 (p=0.341)
CEUS	Da	34 (97.1%)	17 (81.0%)	18 (78.3%)	3 (60.0%)	72 (85.7%)	V=0.31 (p=0.049)
Tip APHE CEUS	Izocaptanta	2 (5.9%)	1 (6.2%)	1 (5.9%)	0	4 (5.7%)	V=0.05 (p=0.979)
	Hipercaptanta	32 (94.1%)	15 (93.8%)	16 (94.1%)	3 (100%)	66 (94.3%)
Caracterizare APHE CEUS	Inomogen	1 (20.0%)	5 (83.3%)	2 (100%)	0 (NA)	8 (61.5%)	V=0.68 (p=0.047)
	Omogen	4 (80.0%)	1 (16.7%)	0	0 (NA)	5 (38.5%)
Viteza APHE CEUS	Lent impreuna cu parenchimul	1 (14.3%)	0	1 (100%)	0 (NA)	2 (16.7%)	V=0.70 (p=0.054)
	Rapid, intens	6 (85.7%)	4 (100%)	0	0 (NA)	10 (83.3%)
Wash out FFH CEUS	Da	32 (94.1%)	14 (87.5%)	16 (100%)	3 (100%)	65 (94.2%)	V=0.19 (p=0.478)
Tip wash out FFH CEUS	Precoce	2 (6.5%)	3 (21.4%)	0	0	5 (7.7%)	V=0.29 (p=0.141)
	Tardiv	29 (93.5%)	11 (78.6%)	17 (100%)	3 (100%)	60 (92.3%)
LiRADS CEUS	2	0	0	0	0	0	V=0.13 (p=0.915)
	3	1 (3.1%)	0	0	0	1 (1.6%)
	4	4 (12.5%)	3 (21.4%)	2 (16.7%)	0	9 (14.8%)
	5	27 (84.4%)	11 (78.6%)	10 (83.3%)	3 (100%)	51 (83.6%)
μ ±SD = Mean (standard deviation); M (range) = Median (min:max); Welch = Welch T-Test (not assuming equal variances); OR/RR = odds-ratio / risk-ratio [95% CI] and p value from Fisher test);

0.6 Figuri

1 References

1. R Core Team (2019). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/.